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SUMMARY OF THE RELATIVE EFFECTIVENESS OF MIDOSTAURIN 
 
Scope 
The scope can be found here: Scope 
Introduction 
This is the assessment of the relative effectiveness of midostaurin in combination with standard 
daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy for 
patients in complete response, followed by midostaurin monotherapy for adult patients with newly 
diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive. Relevant alternative 
therapies had been established based on European guidelines and recommendations.  
Methods 
The objective in the clinical effectiveness and safety domains of this assessment was to identify 
studies related to the beneficial and harmful effects of midostaurin and its relevant comparators 
for the treatment of adult patients with newly diagnosed AML who are fit for intensive chemother-
apy. The manufacturer provided a systematic literature review of the evidence, which was critical-
ly assessed by authors of this assessment.  
The following electronic databases were included in the marketing-authorisation holder (MAH) 
literature search: Embase, via the Embase.com platform; the Cochrane Library database Central 
Register of Controlled Trials; Medline and Medline InProcess and electronic publications ahead of 
print via PubMed; and clinicaltrials.gov, WHO (International Clinical Trials Registry Platform me-
taregistry) and European (EU Clinical Trials Register) registries. Hand-searches included confer-
ence proceedings for the American Society of Hematology 2016 and European Hematology As-
sociation 2016/17 (searched for abstracts and e-posters) and reference lists of included publica-
tions. The final search of databases was performed on 7th June 2017 and final congress search-
es were performed on 26th June 2017. The search protocol was included as part of the submis-
sion. 
Overall, the authors considered that the reporting of the search followed the requirements of the 
EUnetHTA guidelines and reporting Items for Systematic Reviews and Meta-analyses (PRISMA-
P) statement. The search was conducted approximately 2 months before the start of the assess-
ment, and was considered to be up to date. 
In total, three studies (RATIFY, IIT (AMLSG 16-10 / CPKC412DE02T) and UK NCRI AML17 trials) 
were included in the assessment. Risk of bias assessment was conducted at both the study and 
outcome level for RCTs by the authors of this assessment. GRADE was used to assess the quali-
ty of evidence by authors. 
Data and results for RATIFY and IIT studies were included in the MAH submission file. According 
to MAH, these data were presented in the submission file as in the CSR. Results for the UK NCRI 
AML17 trial were extracted from the publications by the authors. Direct comparisons were repre-
sented as in the MAH submission file. Indirect comparison of midostaurin with standard induction 
(“7+3 regimen) and consolidation therapy versus induction (“10+3 regimen) and consolidation 
chemotherapy with high-dose daunorubicin (90 mg/m2/day) during induction was performed by 
the authors using the Bucher method according to the EUnetHTA guideline. In the AML17 ran-
domisation scheme, FLT3 patients had a second course with daunorubicin 50 mg/m2/day plus 
cytarabine +/- lestaurtinib and one or two further courses of high dose cytarabine. 
 
Results 
Description of technology and comparators 
Midostaurin is a new orally administrated multi-target receptor tyrosine kinase inhibitor [B0001]. It 
was designated as an orphan medicinal product on 29th July 2004. Midostaurin received a posi-
tive CHMP opinion from the European Medicines Agency (EMA) on 20th July 2017. Marketing 
authorisation (EC decision) was granted for midostaurin on 18th September 2017 for the following 
indication: in combination with standard daunorubicin and cytarabine induction and high-dose 
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cytarabine consolidation chemotherapy, and for patients in complete response followed by 
midostaurin single-agent maintenance therapy, for adults with newly diagnosed AML who are 
FLT3 mutation positive. Midostaurin gained regulatory approval from the US Food and Drug Ad-
ministration (FDA) on 28th April 2017 and from Swissmedic on 4th May 2017 followed by Health 
Canada approval on 21st July 2017 and EU approval (EC decision) on 18th September 2017. 
While the FDA and Health Canada approvals were restricted to the induction and consolidation 
phase, the EMA and Swissmedic approvals included induction, consolidation and the mainte-
nance phases [A0020]. 
The marketing authorisation application (MAA) for midostaurin included a second indication as 
monotherapy for the treatment of adults with aggressive systemic mastocytosis, systemic masto-
cytosis with associated haematological neoplasm, or mast cell leukaemia. This indication is not 
relevant for this relative efficacy assessment and is not considered in the report. [A0020] 
Midostaurin will be available as 25-mg soft capsules. The recommended dose of midostaurin in 
AML is 50 mg twice daily on days 8–21 of each cycle of induction and consolidation chemothera-
py, followed by 50 mg daily as a single agent for up to 12 months. 
Currently, there are several treatments recommended for AML, but none is specific for FLT3 mu-
tation-positive AML. The following treatments were considered the most-relevant comparators: 
standard induction and consolidation chemotherapy (cytarabine in combination with daunorubicin 
60 mg/m2/day during the induction phase) and induction and consolidation chemotherapy with 
daunorubicin 90 mg/m2/day during the induction phase, as recommended by the Norwegian 
guidelines (Appendix 1,Table A8) [B0001]. 
Health problem 
The health condition relevant for the present assessment is newly diagnosed FLT3 mutation-
positive AML. AML is a haematological malignancy characterised by abnormal growth of haema-
topoietic cells of myeloid lineage in the bone marrow, blood and other tissues. Overall, the 5-year 
survival rate for AML is 20%–30%. Younger patients have better outcomes compared with older 
patients. Patients with FLT3 mutation-positive AML have worse outcomes for overall survival 
(OS), time to relapse and disease-free survival (DFS) compared with patients without FLT3 muta-
tion-positive disease. [A0007] 
AML is a rare condition, with an estimated incidence of 3.7 per 100,000 for the EU overall, and is 
mainly diagnosed in older patients. Approximately one-third of patients have FLT3 mutation-
positive disease. [A0023]. 
 
Clinical effectiveness 
Available evidence 
The assessment of clinical effectiveness was based on three studies: RATIFY trial, IIT-trial and 
UK NCRI AML17 trial.  
RATIFY was a randomised phase III study of induction (daunorubicin/cytarabine) and consolida-
tion (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-
naive patients with FLT3-mutated AML. In total, 717 patients aged 18–60 years were included in 
the full analysis set of the trial. This was the most important study to this assessment and is the 
pivotal trial of midostaurin this indication.  
Investigator-initiated trial (IIT trial, AMLSG 16-10 / CPKC412DE02T) is a single-arm phase II trial 
involving 145 patients (aged 18–70 years) receiving midostaurin with standard induction and con-
solidation therapy. This study provided supporting data especially on older patients (over 60-years 
old). These data were mainly used to characterise the treatment outcomes in an older population. 
The UK NCRI AML17 trial compared standard chemotherapy with daunorubicin 60 mg/m2 to high-
dose daunorubicin. The trial was terminated prematurely due to a significantly higher 60-day mor-
tality rate observed in the 90 mg/m2 vs 60 mg/m2 daunorubicin group in the overall study popula-
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tion, not restricted to patients with FLT3 mutation. However, there was a significant interaction in 
the effect by FLT3 mutation. The results of the post-hoc exploratory subgroup analysis consider-
ing FLT3 positive patients (n=200, median follow-up of 28 months) of this study were applied only 
to the indirect comparisons related to OS. 
Overall survival [D0001] 
In the RATIFY trial, the risk of death was reduced by 23% during the follow-up for the midostaurin 
versus placebo groups (HR 0.77 [95% CI 0.63–0.95]; p=0.0078). The proportion of patients alive 
in the midostaurin and placebo treatment arms were: 
 1 year – 76% (95% CI: 0.72–0.81) versus 68% (95% CI: 0.62–0.72) 
 5 years – 51% (95% CI: 0.45–0.56) versus 43% (95% CI: 0.38–0.49) 
 
Similar to the OS results, results for OS censored at SCT showed a reduced risk of death for pa-
tients treated with midostaurin over placebo (HR 0.75 [95% CI: 0.54–1.03]; p=0.0373). 
In the single-arm IIT trial, the proportion of younger patients (≤60 years) alive was 53.7% at the 2-
year follow up. The proportion of older patients (>60 years) was 45.2%. The median survival was 
28.5 months and 15.5 months, respectively. 
A difference in OS effect was observed for men versus women in a prespecified subgroup analy-
sis (HR=0.53 [95% CI: 0.39–0.72] for men and HR=1.01 [95% CI: 0.76–1.34] for women). This 
heterogeneity was not observed in other efficacy endpoints. No other relevant heterogeneity in the 
OS effect was observed in the subgroup analyses, including SCT status (undergoing SCT or not 
undergoing SCT) and NPM1 status (mutated or wild type). 
Indirect results comparing daunorubicin 90 mg/m2 in the first induction cycle ("10 + 3" regimen) 
followed by a second course and consolidation versus midostaurin plus standard induction ("7 + 
3" regimen) and consolidation, showed no difference between the treatments in terms of OS 
(HR=0.84 [95% CI: 0.54–1.31]). However, several serious limitations apply to this indirect compar-
ison. 
 
Disease progression, treatment response and relapse rate [D0006] 
Event-free survival (EFS) was improved by 27% compared with standard induction and consolida-
tion chemotherapy (HR=0.73, 95% CI: 0.61–0.87, p=0.0001). EFS results censored at SCT were 
consistent with this result (HR=0.76, 95% CI: 0.63–0.92, p=0.0019). The effect of midostaurin on 
EFS was homogeneous across the subgroups. In the IIT trial, median EFS was 13.8 months in 
patients aged ≤60 years and 9.3 months in patients over 60 years of age.  
Disease-free survival (DFS) from first complete remission (CR) was improved by 34% compared 
with standard induction and consolidation chemotherapy (HR= 0.66, 95% CI: 0.52–0.85, 
p=0.0006) and DFS censored at SCT improved by 28% compared with standard induction and 
consolidation chemotherapy (HR=0.72, 95% CI: 0.54–0.97, p=0.0150).  
Overall, the CR rate was higher in the midostaurin group than in standard induction and consoli-
dation chemotherapy (65% versus 58%, p=0.027, one sided). In the IIT trial, a slightly higher pro-
portion of patients in CR was observed in patients ≤60 years of age than in patients over 60 years 
of age (77% vs. 67%). 
Comparison of the cumulative incidence of relapse (CIR) between the two treatment groups 
showed that midostaurin reduced the risk of relapse compared with standard induction and con-
solidation chemotherapy (HR 0.676 [95% CI: 0.52–0.89]; p=0.0023). Censoring for SCT reduced 
the difference between the treatment groups (HR 0.761 (0.561–1.031); p=0.0387). 
Generic and disease-specific quality of life [D0012, D0013] 
There were no results available on the effect of midostaurin on the generic health-related quality 
of life or disease-specific quality of life. Quality-of-life aspects have not been investigated in the 
studies completed to date. 
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Safety 
All patients in the RATIFY trial experienced at least one adverse effect (AE) of any grade regard-
less of relation with the study drug. All patients in the placebo group and all except one patient in 
the midostaurin group experienced grade 3–4 AEs. Approximately 50% of the patients in both 
groups experienced a serious AE (SAE) and approximately 75% of patients in both groups report-
ed at least one grade 3–4 AE considered to be related to treatment. Most AEs were reported dur-
ing the induction and consolidation phases and were less frequently reported during the continua-
tion phase. There were 36 deaths-on-treatment (i.e., within 30 days of the last treatment; 15 and 
21 in the midostaurin and placebo arms, respectively). [C0008] 
 
The most-frequent treatment-related grade 3–4 AEs were thrombocytopaenia, neutropaenia, 
anaemia and febrile neutropaenia. The events leading to discontinuation in more than one patient 
were dermatitis exfoliative, increased ALT, increased AST, decreased neutrophil count and renal 
failure in the midostaurin group, and febrile neutropaenia and decreased neutrophil count and 
decrease platelet count in the placebo group. Overall, 23 (6.7%) patients in the midostaurin group 
and 17 (5.1%) patients in the placebo group discontinued therapy because of grade 3–4 AEs. 
[C0008] 
Based on the safety results from the IIT trial, the treatment-related AEs and their severity were 
similar in patients aged ≤60 years and those aged >60 years. The incidence of SAEs and discon-
tinuation because of AEs were higher in older patients. Deaths occurred at a higher frequency in 
patients aged >60 years. [C0008] 
Grade 3–4 AEs occurring more frequently in the midostaurin group than in the placebo group 
were exfoliative dermatitis and device-related infections. Furthermore, an increased frequency of 
QTc prolongation has been observed in patients receiving midostaurin. A mechanistic explanation 
for this observation was not found. [C0008] 
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Table S.0.1: Summary of key results 
Outcome Anticipated absolute effects Relative 
effect (95% 
CI) 
Number of 
participants  
(studies) 
Quality Comments 
Risk with midostaurin with 
standard induction and 
consolidation 
chemotherapy 
Risk with standard 
induction and 
consolidation 
chemotherapy 
OS 
1-year survival: 760 per 1000 
3-year survival: 540 per 1000 
5-year survival: 510 per 1000 
1-year survival: 680 per 1000 
3-year survival: 470 per 1000 
5-year survival: 430 per 1000 
HR 0.77  
[0.63–0.95] 
717 (1) High 
Indirect results comparing daunorubicin 90 
mg/m2 in the first induction cycle ("10 + 3" 
regimen) followed by a second course and 
consolidation versus midostaurin plus standard 
induction ("7 + 3" regimen) and consolidation, 
showed no difference between the treatments 
in terms of OS (HR=0.84 [95% CI: 0.54–
1.31]).However, serious limitations apply to 
this indirect comparison. These include limited 
similarity of the treatments in the reference 
arms, difference in the follow-up times and 
partly unknown characteristics of the patient 
population in the FLT3 positive subgroup of 
UK NCRI AML 17 trial. 
OS, censored for 
SCT 
1-year survival: 820 per 1000 
3-year survival: 650 per 1000 
5-year survival: 640 per 1000 
1-year survival: 700 per 1000 
3-year survival: 580 per 1000 
5-year survival: 560 per 1000 
HR 0.75  
(0.54–1.03) 
717 (1) High  
EFS 
1-year survival: 470 per 1000 
3-year survival: 320 per 1000 
5-year survival: 310 per 1000 
1-year survival: 330 per 1000 
3-year survival: 230 per 1000 
5-year survival: 210 per 1000 
HR=0.73 
(0.61–0.87) 
717 (1) High  
DFS (from first 
CR) 
1-year survival: 700 per 1000 
3-year survival: 490 per 1000 
5-year survival: 480 per 1000 
1-year survival: 540 per 1000 
3-year survival: 380 per 1000 
5-year survival: 360 per 1000 
HR=0.66  
(0.52–0.85) 
717 (1) High  
CR (all CRs 
occurring during 
induction) 
650 per 1000 580 per 1000 
RR=1.12  
(1.00–1.26) 
717 (1) High  
CIR — — 
HR=0.68 
 (0.52–0.89) 
717 (1) High  
Death as SAE 43 per 1000 63 per 1000 
— 717 (1) 
Not 
assessed 
Deaths on treatment includes those occurring 
within 30 days of discontinuation of treatment. 
 
SAE 470 per 1000 487 per 1000 
Grade 3–4 AEs 997 per 1000 1000 per 1000 
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Outcome Anticipated absolute effects Relative 
effect (95% 
CI) 
Number of 
participants  
(studies) 
Quality Comments 
Grade 3–4 AEs 
suspected to be 
related to 
treatment 
780 per 1000 752 per 1000 
Grade 3–4 exfoliative dermatitis and device-
related infections occurred more frequently in 
midostaurin-treatment group 
QTc prolongation has been observed in 
patients receiving midostaurin Withdrawal 
because of 
grade 3–4 AEs 
61 per 1000 45 per 1000 
HrQoL Not available Not available Not available    
Abbreviations: see List of abbreviations. 
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Discussion 
 
Scope of the assessment 
The following treatments were considered the most-relevant comparators: (i) standard induction 
and consolidation chemotherapy (cytarabine in combination with daunorubicin 60 mg/m2/day dur-
ing the induction phase); and (ii) induction and consolidation chemotherapy with daunorubicin 
90 mg/m2/day during the induction phase. [B0001] 
SCT, azacitidine and gemtuzumab ozogamicin (GO) were identified as potential treatment options 
(comparators) during the early scoping for this assessment. However, these comparators were 
excluded from the assessment because: (i) azacitidine is used in patients who are not suitable for 
intensive chemotherapy and, thus, this does not represent the patient group that was defined in 
the scope of this assessment; (ii) SCT is widely used for patients with AML who are suitable for 
SCT. However, because midostaurin and SCT treatments are not mutually exclusive treatment 
options, SCT was not included in PICO. SCT is considered for all eligible patients irrespective of 
the use of midostaurin; and (iii) GO was considered by the MAH as a relevant comparator be-
cause it has been prescribed in France as part of a compassionate-use program since 2014 [1]. 
However, it was not considered in this assessment as a relevant comparator because of its limited 
use in selected patients in only one member state. 
Effectiveness 
Midostaurin in combination with standard induction and consolidation chemotherapy improved OS 
in patients aged 18–60 years who were fit for chemotherapy. However, because of a plateau ef-
fect in the OS curves, the absolute OS gain was difficult to determine reliably. SCT is unlikely to 
significantly confound the effect of midostaurin on OS, despite the high rate of patients receiving 
SCT. Overall, key secondary outcomes support the conclusions based on the primary outcome 
(OS). No data on the health-related quality of life or disease-specific quality of life were available, 
which is a severe evidence gap. [D0001] Hower, according to MAH, quality of life data are being 
collected in the IIT and this data will become available once the study is completed. 
There was no relevant heterogeneity in the effect on OS observed in the subgroup analyses, ex-
cept for a difference between males and females. This difference was not fully discussed in the 
submission file. [D0001] This heterogeneity was not observed in other efficacy endpoints. 
Based on the indirect comparison of midostaurin in combination with standard induction (“7 + 3 
regimen”) and consolidation chemotherapy versus high-dose (90 mg/m2) daunorubicin induction 
(“10 + 3 regimen”) and consolidation chemotherapy, there was no evidence that midostaurin 
treatment was more beneficial than high-dose daunorubicin used during induction, or vice versa. 
However, serious limitations apply to this indirect comparison. These include limited similarity of 
the treatments in the reference arms, difference in the follow-up times and partly unknown charac-
teristics of the patient population in the FLT3 positive subgroup of UK NCRI AML 17 trial. Risk of 
bias at study and outcome level was also observed related to UK NCRI AML 17 trial subgroup 
analysis. Furthermore, the high-dose daunorubicin used during induction does not represent the 
gold standard of treatment across Europe. 
Safety 
Overall, AEs were balanced between the patient groups, although rates of grade 3–4 AEs were 
high. However, this is a typical outcome, given the health condition of the patients in these trials. 
Grade 3–4 AEs emerging more frequently in the midostaurin group than in the placebo group 
were exfoliative dermatitis and device-related infections. Furthermore, QTc prolongation has pre-
viously been observed in patients receiving midostaurin. [C0008] 
Ethical, organisational, social and legal aspects 
No potential concerns were identified in terms of ethical, organisational, social or legal aspects 
that would be related to using midostaurin with standard induction and consolidation chemothera-
py. All patients receiving midostaurin must be tested for FLT3 mutation. However, this testing is 
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not currently implemented Europe-wide, which could impact the use of this treatment in some 
countries. 
Applicability and quality of evidence 
Overall, evidence for the OS effect of midostaurin with standard induction and consolidation 
chemotherapy versus standard induction and consolidation chemotherapy alone was based on 
only one appropriately designed and analysed RCT with a low risk of bias. The direct evidence is 
of high quality. However, the indirect comparison of midostaurin has several limitations and the 
overall quality of evidence is low. Given the design of the RATIFY trial, the disposition of patients 
and the complex treatment regimen overall, the effects of midostaurin during continuation therapy 
are difficult to assess reliably. Only a small proportion of patients received midostaurin as contin-
uation therapy. 
RCT evidence was only available for patients aged 18–60 years (45.2 years on average), which 
was younger than patients typically treated in clinical practice across Europe. In addition, the pro-
portion of patients undergoing SCT in the RATIFY trial is likely to be higher than those treated in 
clinical practice. This might be a reflection of a younger and healthier patient population recruited 
in the clinical trial. There is only limited evidence from patients over 60 years of age and this is 
based on a single-arm trial. By contrast, given these results, there is no reason to suspect that 
patients aged 60 years or more would not benefit from midostaurin. Instead of age, patient’s fit for 
chemotherapy is more critical in terms of their eligibility for treatment. However, there is a clear 
evidence gap concerning the effects of midostaurin in older patients and the effect size in this 
population remains unknown.  
Another issue related to the applicability of the results is the variation in the standard induction 
and consolidation chemotherapy regimens used across countries and regions. The most common 
therapies for AML comprise a combination of an anthracycline and continuous infusion of cytara-
bine and/or stem cell transplantation, depending on the risk group. Several anthracyclines at dif-
ferent dosages are recommended for use across Europe (e.g., idarubicin). Mitoxantrone can be 
also used instead of daunorubicin. Midostaurin has been studied in combination with standard 
daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and 
with patients in complete response followed by midostaurin monotherapy. There is no evidence of 
the effects of midostaurin in combination with other induction and consolidation alternatives ex-
cept those used in the RATIFY trial. In addition, the indication of midostaurin is restricted to spe-
cific induction and consolidation chemotherapy. 
Conclusion 
Based on the results of this assessment, midostaurin in combination with standard induction and 
consolidation chemotherapy is considered to be more effective than standard induction and con-
solidation chemotherapy alone. More uncertainty is related to the beneficial effects of midostaurin 
used in continuation therapy because of patient disposition in the trials assessed, leading to fewer 
patients receiving continuation therapy. Based on indirect comparison, there was insufficient evi-
dence to determine whether midostaurin treatment was more beneficial than high-dose dauno-
rubicin (90 mg/m2) used during induction in terms of OS. Serious limitations apply to this compari-
son. Patients over 60 years of age have not yet been studied in an RCT setting and the effect size 
of midostaurin on OS is unknown in this older population. However, it is the suitability of patients 
for intensive chemotherapy, rather than their age, which is the limiting factor to midostaurin use.  
The safety profile of treatment with midostaurin in combination with standard induction and con-
solidation chemotherapy is considered to be comparable to standard induction and consolidation 
chemotherapy. However, grade 3–4 exfoliative dermatitis and device-related infections occurred 
more frequently in patients receiving midostaurin. Furthermore, QTc prolongation has been ob-
served in patients receiving midostaurin. Deaths during the study treatment and 30-day follow-up 
periods occurred more frequently in patients over 60 years of age compared with those who were 
younger. 
Further research is required on the effects of midostaurin in the older population. Health-related 
quality of life and disease-specific quality of life should be studied, because this evidence is cur-
rently lacking. 
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1 SCOPE 
 
Description Project scope 
Population  Adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 
mutation positive. 
ICD-10: C92.0 
Mesh-terms: Leukaemia, Myeloid, Acute 
Tree Number(s): C04.557.337.539.275 
MeSH Unique ID: D015470 
Intervention There are three parts to the intervention: 1) induction therapy, 2) consolidation ther-
apy and 3) continuation therapy. Eligible patients may receive SCT. 
1) Induction therapy: 
• cytarabine 200 mg/m2/day intravenously on days 1–7. 
• daunorubicin 60 mg/m2/day intravenously on days 1–3. 
• midostaurin 50 mg (two 25-mg capsules) twice daily orally on days 8–21. 
2) Consolidation (four remission consolidation cycles): 
• high-dose cytarabine 3 g/m2 every 12 h on days 1, 3 and 5.  
• midostaurin 50 mg (two 25-mg capsules) twice daily orally on days 8–21. 
• dexamethasone 0.1% or other corticosteroid ophthalmic solution 2 drops to each 
eye once daily to begin 6–12 h before initiation of cytarabine infusion and to contin-
ue for at least 24 h after last cytarabine dose. 
3) Continuation therapy: 
• midostaurin 50 mg (two 25-mg capsules) orally twice daily for 28 days. Each cycle 
will be 28 days in length. Continuation therapy will continue until relapse or for 12 
cycles maximum. 
Note: In clinical practice, variations might occur in the induction and consolidation 
therapy. For example, idarubicin might replace daunorubicin as an anthracycline, 
dose of cytarabine might vary both in the induction and consolidation therapy. De-
pending on line of the induction and consolidation therapy (i.e., first induction, sec-
ond induction etc.), variations might occur and mitoxantrone might be added during 
the second induction or third consolidation. 
MeSH terms: midostaurin (MeSH Unique ID: C059539) 
Comparison  standard induction and consolidation chemotherapy (see above). Eligible 
patients might receive SCT. 
 induction and consolidation chemotherapy, except daunorubicin 90 
mg/m2/day (instead of 60 mg/m2/day) is used in induction. 
 Maintenance therapy: placebo. 
Outcomes Overall survival (OS) 
Overall survival (OS) censored at SCT: censoring patients who receive a stem 
cell transplant at the time of the transplant. 
Event-free survival (EFS): defined as the time from randomisation until the earliest 
qualifying event, including: failure to obtain a CR during induction; relapse; or death 
from any cause. 
Disease-free survival (DFS): defined as the time from documentation of first CR at 
any time to the first relapse or death from any cause in patients who achieved a CR. 
Complete remission rate (CR): the percentage of patients who achieved a com-
plete response (CR). CR is defined as normalisation of blood counts and a bone 
marrow sample showing less than 5% blasts 
Cumulative incidence of relapse (CIR): the percentage of patients who relapsed 
(a bone marrow sample showing more than 5% blasts) after achieving CR. 
Proportion of patients who discontinued the treatment: the percentage of pa-
tients who discontinued the treatment based on the reason for discontinuation (e.g., 
failure to achieve complete remission, relapse, adverse event, etc.). 
Health-related quality of life (HRQL): generic and disease-specific HRQL 
Adverse events (AEs): any AEs, serious AEs (SAE), Grade ≥3 AEs, Discontinua-
tion because of AE, death as SAE, AE of special interest. 
Note! Additional outcomes may be considered based on data presented in the 
submission or CSR.  
Abbreviations: see List of abbreviations. 
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2 METHODS AND EVIDENCE INCLUDED  
 
The objective of the literature review was to identify studies related to the beneficial and harmful 
effects of midostaurin and its relevant comparators for the treatment of patients with newly diag-
nosed FLT3 mutation-positive AML who are fit for chemotherapy (see Scope). The manufacturer 
provided a systematic literature review of the evidence, which was critically assessed by members 
from the assessment team. The approach used by MAH is characterised in sections 2.3–2.5.  
2.1 Assessment team 
FIMEA acted as the main author, and was responsible for writing the clinical effectiveness and 
safety domains, including the discussions related to these domains. NOMA acted as the co-author 
and was responsible for writing the technical characteristics and health problem and current use 
domains, including the discussions related to these domains. 
Dedicated reviewers (AEMPS, ZINL, TLV, NICE, HAS and IQWIG) reviewed the drafts of the pro-
ject plan and the assessment report and commented on the presubmission material. IQWIG con-
tributed only to reviewing information retrieval. 
2.2 Source of assessment elements 
The assessment elements are defined in the from HTA Core Model version ‘Rapid Relative Effec-
tiveness Assessments (4.2)’. 
2.3 Search 
Objectives of MAH’s systematic literature search 
The literature search was performed by MAH and was included in the submission. The search 
was performed to answer the following questions:  
What published, or unpublished, randomised, controlled trials (RCTs) of induction therapies – 
either licensed in Europe, recommended by European guidelines or agents in development com-
pared to a recommended therapy – have been conducted, or are ongoing, for use in patients with 
newly diagnosed (previously untreated) FLT3 mutation-positive AML who are fit for intensive 
chemotherapy? 
What are the current guidelines in Europe or the US for standard of care for induction and consol-
idation therapy in patients with AML who are fit for intensive chemotherapy? 
Eligibility criteria in MAH’s literature search 
MAH selected studies for inclusion based on the criteria presented in Table 2.1 and Table 2.2. 
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Table 2.1. Systematic review inclusion criteria used in the MAH’s systematic literature re-
view 
Characteristic Inclusion criteria 
Publication type Original articles 
Errata 
Languages Any EU language 
Population Adults (≥18 years) with newly diagnosed FLT3-mutated AML fit for intensive 
chemotherapy 
[AML includes non-APL AML, acute erythroid leukaemia/Di Guglielmo syndrome 
and acute monocytic or monoblastic leukaemia] 
Interventions  Induction therapy (first or second induction), with or without HGFs, with an agent 
either licensed in Europe, recommended by European guidelines or agents in 
development compared with a recommended therapy  
Anthracycline (idarubicin 10–12 mg/m2 or daunorubicin 45–90 mg/m2) + 
cytarabine 100–200 mg/m2/day: 7+3 or 10+3 or 5+2 regimens eligible 
Mitoxantrone 12 mg/m2 
First-generation FLT3i (SOR, Rydapt®, LEST) 
Second-generation FLT3i (QUIZ, CREN, GILT) 
GO 
Studies following up patients after induction through consolidation therapy were 
also eligible.  
Comparator Induction therapy with standard-of-care chemotherapy recommended by 
European guidelines or placebo/no chemotherapy, with or without follow-up 
through consolidation therapy 
Outcomes OS 
EFS 
Rate of CR 
DFS 
RFS 
Rate of SCT 
Duration of treatment 
Treatment-related mortality  
On-treatment deaths 
Early death 
Infectious complications 
Treatment interruptions or dose changes 
Discontinuation (any cause) 
Discontinuation (because of AEs) 
SAEs (irrespective of whether possibly drug related) 
SAEs (possibly drug related) 
Grade 3–4 toxicities 
Grade 3–5 toxicities 
HrQoL 
Quality of complete response (e.g., minimal residual disease negative) 
Leucopoenia – anaemia, WBC count, absolute neutrophil/neutropaenia 
Severe infections: incidence density of (any) infections, malaria, tuberculosis, viral 
hepatitis, hepatitis C virus, pneumonia, blood infections, gastrointestinal infections, 
lung infections, invasive lung infection 
Pulmonary toxicity: pleural effusion, interstitial lung disease, pneumonitis 
Cardiac dysfunction/failure: LVEF change from baseline 
Study design Completed RCTs and ongoing RCTs (phase IIa, III or IV) 
Current European guidelines from 2006b or recent reviews (for reference cross-
checking and identification of guidelines) 
Date limits Unlimited 
Abbreviations: see List of abbreviations. 
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Table 2.2. Systematic review exclusion criteria used in the MAH’s systematic literature re-
view 
Characteristic Exclusion code and criterion 
Publication 
type 
 Not an original article 
Duplicate  Duplicate/copy 
Languages  Not an EU language 
Population  Paediatric disease (<18 years) 
 Acute promyelocytic leukaemia  
 Acute mast cell leukaemia 
 Myelodysplastic syndrome  
 Chronic myeloid leukaemia 
 Relapsed/refractory/drug-resistant disease 
 Patients randomised within first remission  
 Preleukaemic syndromes/myeloproliferative neoplasm/syndromes not trans-
formed into AML 
 Down syndrome 
 Acute megaloblastic leukaemia 
 Core binding factor AML 
 Animal studies 
Mixed 
populations 
 Mixed child/adult population or mixed AML/other population with <80% of pa-
tients from the population of interest and subgroup data not reported 
Interventions  Patients randomised to intervention at consolidation, post remission, peri- or 
post HSCT or at maintenance stage of therapy 
 Intervention neither a current SoC in Europe nor a new agent/dose in develop-
ment 
 Radiation 
 Azacitidine 
Comparators  Comparator not a SoC in Europe according to treatment guidelines  
 Radiation 
Outcomes  Does not include outcome listed in Table 2.1 
 Outcomes reported only for the pooled treatment arms (not for each arm individ-
ually) were excluded, but tagged (listed in report) 
 No numeric data reported (tagged and listed in report) 
Studies  Not RCTs or guidelines 
 Observational study (e.g., cohort, case-control, database study) 
 Pilot study (even if RCT) 
 Study not intended to be powered to detect a statistically significant difference 
between treatment arms for the primary endpoint (even if RCT) 
 Single-arm studies 
 Case reports 
 Case series 
 Expanded treatment protocols 
 Expanded access programs 
 Phase I trial 
 Phase I/II trial and the publication reports only phase I data 
 Studies validating the real-world effects of implementing guidelines from any Eu-
ropean country were excluded, but tagged 
Abbreviations: see List of abbreviations. 
 
Information sources and search strategy in MAH’s literature search 
The following electronic databases were included in the MAH literature search: Embase, via the 
Embase.com platform; the Cochrane Library database Central Register of Controlled Trials; Med-
line and Medline InProcess and electronic publications ahead of print via PubMed; clinicaltri-
als.gov, WHO (International Clinical Trials Registry Platform meta-registry) and European (EU 
Clinical Trials Register) registries. Hand-searches included conference proceedings for American 
Society of Hematology 2016 and European Hematology Association 2016/17 (searched for ab-
stracts and e-posters) and reference lists of included publications and further hand-searching as 
summarised in Appendix 1. Search strings and strategies are also included in Appendix 1. The 
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final search of databases was performed on 7th June 2017 and final congress searches were 
performed on 26th June 2017. The search protocol was included as part of the submission. 
Authors’ view on the search performed by MAH 
Overall, the reporting of the search followed the requirements of the EUnetHTA guidelines and 
reporting Items for Systematic Reviews and Meta-analyses (PRISMA-P) statement [2]. The 
search covered the relevant databases and was conducted approximately 2 months before the 
start of the assessment, and can be considered up to date. 
During the review, it was noted that MAH literature search on study registries might not be sensi-
tive enough to find all eligible studies, and consequently it was uncertain whether the evidence 
base is complete. The study pool of midostaurin was checked by the authors with a handsearch in 
ClinicalTrials.gov 5.9.2017. No further relevant studies could be identified. 
2.4 Study selection 
Selection process used in MAH’s literature review 
First-pass screening on the basis of title/abstract was performed by MAH as per the eligibility cri-
teria (Table 2.1 and Table 2.2) using the following steps: screening of the references by ti-
tle/abstract, a revisit to all the ‘Excludes’ by another analyst to ensure the inclusion of all relevant 
studies, and senior review for authentication of the results and resolution of the queries. Full pa-
pers were reviewed by two researchers independently to confirm their eligibility. Uncertainties 
were discussed with an adjudicator and resolved. Where a paper remained borderline, a third 
appropriate reviewer would adjudicate. The primary publication for any study was taken as the 
first full paper reporting the primary outcome. Other citations for the same study were termed 
‘linked’ citations. Linked citations that offered no unique information or that were superseded by 
either earlier or later publications were excluded during screening. Linked citations offering unique 
information were included and reported in a table, indicating which unique data were reported. A 
PRISMA diagram for the systematic literature search performed by MAH is presented in Figure 
2.1. 
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Figure 2.1. PRISMA diagram for the systematic literature search.   
 
Characteristics of studies found in the literature review 
In total, 11 RCTs reporting results were identified Table 2.3. Short et al. [3] did not report results 
and this study is not listed in Table 2.3. One study investigated therapy specifically in patients with 
FLT3 mutation-positive AML. This was a phase III study reporting the efficacy and safety of 
midostaurin in combination with daunorubicin and cytarabine. Results of this study were reported 
in [4]. Further details were provided to authors during the MAH submission, including CSRs. One 
study did not report its results. The remaining nine studies reported data for subgroups of patients 
with FLT3 mutation-positive tumours. 
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Table 2.3. List of relevant publications found in the literature search 
Reference Interventions Number of FLT3 patients 
RATIFY 
[4]  
(CALGB 10603/ 
CPKC412A2301) 
Intervention: 
Midostaurin with standard induction and 
consolidation therapy followed by maintenance 
therapy with midostaurin 
Comparator 
As above, but placebo instead of midostaurin 
Midostaurin: n=360  
Placebo: n=357 
[5]  
(ECOG E1900 trial) 
Induction 
 D 90 mg/m2+C (100 mg/m2) (7+3) 
 D 45 mg/m2+C (100 mg/m2) (7+3) 
Consolidation 
 Allo-SCT or 
 HDAC (3 g/m2 every 12 h every other day 
for a total of 6 doses) ± GO (single dose, 
6 mg/m2) followed by SCT 
FLT3-ITD 
D 90 mg: n=64 
D 45 mg: n=83 
[5, 6] Induction 
 D 90 mg/m2+C (100 mg/m2) 
 D 45 mg/m2+C (100 mg/m2) 
Consolidation 
 Allo-SCT or 
 HDAC (3 g/m2 every 12 h every other day 
for a total of 6 doses) ± GO (single dose, 
6 mg/m2) followed by SCT 
As for [5] 
[7]  
(ALFA-0701 trial) 
Median follow-up: 
14.8 months 
Induction 
 D 60 mg/m2+C (200 mg/m2) (7+3)+GO 
(3mg/m2) 
 D 60 mg/m2+C (7+3) 
 Second induction 
 D 60 mg/m2+C (1g/m2) (7+3)+G-CSF 
Consolidation 
 D 60 mg/m2+ C (7+3)±GO (6 mg/m2) 
FLT3-ITD 
D + C (7+3) + GO: n=22 
D + C (7+3): n=27 
[8]  
(Analysis of 
karyotyping data of 
ALFA-0701 trial 
reported in [7]) 
As for [7] All patients 
FLT3-ITD: n=49 
D + C + GO: =22 
D + C: n= 27 
FLT3-TKD: n=14 
D + C + GO: n= 10 
D + C: n=4 
CN AML 
FLT3-ITD: n=36 
D + C + GO: n=16 
D + C: n=20 
FLT3-TKD: n=5 
D + C + GO: n= 3 
D + C: n= 2 
[9] 
(UK NCRI AML15 
trial) 
Induction 
 ADE (D 50 mg/m2+C 100 mg/m2+E 100 
mg/m2) (10+3+5) ± GO 3 mg/m2 
 D 50 mg/m2+C 100 mg/m2 (3+10)±GO 
 FLAG-Ida±GO 3 mg/m2 
Second induction 
 ADE (D 50 mg/m2) (8+3+5)  
 D 50 mg+C (3+8) 
 FLAG-Ida (F 30 mg/m2+C 2 g/m2+G-CSF+I 
8 mg/m2) 
Consolidation 
 MACE/MidAC (A 100 mg/m2+C 200 
mg/m2+E 100 mg/m2 then M 10 mg/m2+C 
1.0 g/m2)±GO 3 mg/m2 
 C (1.5 g/m2)±GO 3 mg/m2 
 C (3 g/m2)±GO 3 mg/m2 
FLT-ITD 
Induction 
ADE: n=72 
D + C: n=63 
ADE: n=37 
FLAG-Ida: n=34 
At consolidation 
randomisation: 
MACE/MidAC n=37 
C (any dose): n=45 
C (3 g, adults): n=24 
C (1.5 g): n=21 
 
4 courses: n=9 
5 courses: n=5 
[10]  
(UK NCRI AML17 
trial) 
Course 1 
 D 90 mg/m2+C (100 mg/m2) 
 D 60 mg/m2+C (100 mg/m2) 
FLT3-ITD 
D 90 mg: n=100 
D 60 mg: n=100 
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Reference Interventions Number of FLT3 patients 
Course 2 
 D 50 mg/m2+C (100 mg/m2)+LEST 
 D 50 mg/m2+C (100 mg/m2)+P 
Course 3  
 C 100 mg/m2±LEST/Ev 
Course 4 
 LEST ± Ev 
 C 100 mg/m2±LEST/Ev 
[11]  
(Update of NCRI 
AML 17 trial, 
median follow-up of 
28 months) 
As for [10] As for [10] 
[12]  
UK NCRI AML16 
trial 
Induction 
 D 50 mg/m2+Cl 20 mg/m2±GO 3 mg/m2 
 D 50 mg/m2+C 100 mg/m2 (3 + 10)±GO 
mg/m2 
Induction 2 
 D 50 mg/m2+Cl 
 D 50 mg/m2+C 100 mg/m2 (3+8) 
Consolidation 
 D 50 mg/m2+C 100 mg/m2 (2+5) 
 No consolidation 
Maintenance 
 Aza 75 mg/m2 
 No consolidation 
FLT3-ITD 
D + Cl + GO: n=18 
D + C: n=14 
[13] Induction 
 D 60 mg/m2+C 100 mg/m2 (7+3) 
Second induction 
 D 60 mg/m2+C-dose intermediate (1 g/m2) 
(7+3)+S (400 mg BID)±P 
Consolidation 
 C (1 g/m2) 
FLT3-ITD 
S: n=15 
P: n=13 
[14] Induction 
 D 60 mg/m2 + C 100 mg/m2 (3+7) + S 400 
mg BID 
 D 60 mg/m2 + C 100 mg/m2 (3+7) + P 
Second induction 
 D 60 mg/m2 + C (3+7) + S ± HAM (C 3 
mg/m2, M 10 mg/m2) 
 D 60 mg/m2 + C (3+7) + P ± HAM 
Consolidation 
 C (3 g/m2) + S  
 C (g/m2) + P  
Maintenance 
 S or P 
FLT3-ITD 
S: n=23 
P: n=23 
[15] Induction 
 I 12 mg/m2 + C 200 mg/m2 (3+7) 
 D 90 mg/m2 + C 200 mg/m2 (3+7) 
Second induction 
 I 12 mg/m2 + C 200 mg/m2 (2+5) 
 D 45 mg/m2 + C 200 mg/m2 (2+5) 
FLT3-ITD 
I + C, n=27  
D + C, n=17  
[16] Induction 
 CPX-351 100 units/m2 (3) 
 D 60 mg/m2+C 100 mg/m2 (3+7) 
CPX-351 is nano-scale liposomal formulation of 5:1 
molar ratio C and D 
FLT3-ITD/TKD, n=44 
ITD, n=33 
TKD, n=17 
Abbreviations: see List of abbreviations. 
Source: adapted from [17]. 
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Studies included in the assessment 
According to MAH, only one RCT (RATIFY) was considered directly relevant for the assessment, 
because daunorubicin 60 mg/m2 plus cytarabine as induction therapy followed by high-dose cy-
tarabine is considered the main European standard of care and therefore the most relevant com-
parator to midostaurin-based therapy, based on current treatment guidelines.  
However, in this assessment, induction and consolidation chemotherapy with high-dose dauno-
rubicin (90 mg/m2/day instead of 60 mg/m2/day) in induction was also considered as a relevant 
comparator (see section 1, Scope). Consequently, UK NCRI AML17 trial (RCT), including its up-
dated results, were considered relevant to this assessment by the authors and were included in 
the analyses in addition to the RATIFY trial. In the UK NCRI AML17 trial [10, 11], high-dose 
daunorubicin was compared with standard-dose daunorubicin used in induction. All the other RCT 
studies found in the systematic literature review, except the RATIFY and UK NCRI AML17 trials, 
were excluded from analyses because of the lack of relevant comparisons. 
Aside from the literature review for RCTs, a single-arm investigator-initiated trial (AMLSG 16-10, 
referred to as the IIT trial) reported results on the efficacy and safety of midostaurin added to 
daunorubicin plus cytarabine in patients with newly diagnosed FLT3-ITD mutation-positive AML. 
This study involved patients aged 18–70 years and provides supporting data, particularly relating 
to the efficacy and safety of midostaurin in older patients.  
The details and results of IIT trial are included in the submission file. The authors conducted a 
hand-search of clinical trials.gov to find any phase II–III interventional studies with midostaurin in 
AML. No other relevant single-arm studies with results were found, except for the IIT trial. The 
results of the IIT trial were mainly used to characterise the effects in older patients. 
The study selection for studies included in the assessment is presented in Figure 2.2. Details and 
references can be found in Table 2.3 and Table 2.4. 
 
 
Figure 2.2. Selection of studies included in the assessment. The final selection was con-
ducted by the EUnetHTA authors.  
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2.5 Data extraction and analyses 
 
Data extraction 
In the MAH submission, details of the data collection process, outcome prioritisation and plans for 
data synthesis were not explicitly stated, as required in PRISMA-P. 
The data and results for the RATIFY and IIT studies were included in the MAH submission file. 
MAH presented these data as in the CSR. Results for the UK NCRI AML17 [10, 11] trial were 
extracted from the publications by the authors.  
Data synthesis and analyses 
Direct comparisons were represented as in the MAH submission file. Indirect comparison of 
midostaurin with standard induction and consolidation therapy versus induction and consolidation 
chemotherapy with high-dose daunorubicin (90 mg/m2/day) during induction was performed by 
the authors using the Bucher method according to the EUnetHTA guideline [18]. 
2.6 Quality rating  
Risk of bias assessment was conducted at the study and outcome levels for RCTs by the authors. 
GRADE was used to assess the quality of evidence by the authors. See Appendix 1 for details. 
2.7 Patient involvement 
After consultation with patient organisations, a Romanian patient with AML was identified. An 
open interview, based on the HTAi questionnaire template, was conducted with this patient. The 
experiences of the patient informed the outcomes taken into consideration for this Joint Assess-
ment. 
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2.8 Description of the evidence used 
Table 2.4. Main characteristics of studies included. Detailed data tables are included in 
Appendix 1 
Author and 
year or 
study name 
Study  
type 
Number of 
patients 
Intervention (s) Main  
endpoints 
Included in clinical 
effectiveness and/ 
or safety domain 
RATIFY 
(CALGB 
10603/ 
CPKC412A
2301) 
Phase III 
randomise
d, double-
blind 
placebo-
controlled 
study 
Midostaurin 
(n=360) and 
Placebo  
(n=357) 
Intervention: 
midostaurin with 
standard 
induction and 
consolidation 
therapy followed 
by maintenance 
therapy with 
midostaurin 
Comparator: 
as above, but 
placebo instead 
of midostaurin 
OS 
Key secondary 
objective: EFS  
Other 
secondary 
endpoints: CR, 
DFS, CIR, OS, 
EFS and DFS 
censored at 
time of SCT 
Yes 
[10, 11] 
UK NCRI 
AML17 trial 
Phase III 
randomise
d 
controlled 
trial 
Daunorubicin 
90 mg/m2 
n=604 (100 
with FLT3 
ITD)  
Daunorubicin 
60 mg/m2 
n=602 (100 
with FLT3 
ITD) 
Intervention: 
high-dose 
daunorubicin 
(90 mg/m2) in 
induction 
Comparator: 
standard-dose 
daunorubicin 
(60 mg/m2) 
Additional 
treatments 
described in 
Appendix 1. 
Complete 
remission (CR) 
CR duration 
Relapse rate, 
monitored over 5 
years 
Deaths in CR, 
monitored over 5 
years 
Overall survival 
(at 5 years) 
Toxicity 
Quality of life  
Supportive care 
requirements 
Yes (effectiveness 
as applicable) 
Investigato
r-initiated 
trial 
(referred as 
the IIT trial 
in this 
document)  
AMLSG 16-
10, 
CPKC412A
DE02T 
[17, 19, 20] 
Open-
label, 
single-
arm, 
phase II 
study 
n=145 Midostaurin plus 
daunorubicin 
plus cytarabine  
EFS  
Secondary 
outcome 
measures: 
CR 
RFS 
OS 
Yes 
Abbreviations: see List of abbreviations. 
 
2.9 Deviations from project plan 
Azacitidine was excluded from the list of relevant comparators. Azacitidine is used in patients who 
are not suitable for chemotherapy and thus do not represent the patient group that is defined in 
the scope of this assessment. 
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS OF TECHNOLOGY 
(TEC) 
 
3.1 Research questions  
Element ID Research question 
B0001 What is midostaurin and its comparators? 
A0020 What are the approved indications of midostaurin? 
B0002 What is the claimed benefit of midostaurin in relation to its comparators in AML? 
B0003 What is the phase of development and implementation of midostaurin and its comparator(s)? 
3.2 Results 
Features of the technology and comparators 
[B0001] What is midostaurin and its comparators? 
Midostaurin is an orally administrated staurosporine analogue with potent activity against both 
ITD- and TKD-mutant as well as wild-type FLT3. In addition, it also inhibits other molecular tar-
gets, including several isoforms of protein kinase C, KIT, VEGFR-1, FGFR and multidrug re-
sistance gene products implicated in the pathogenesis of AML. Midostaurin inhibits FLT3–
receptor signalling in leukaemic cells that express FLT3-ITD or TKD mutant receptors, leading to 
cell cycle arrest and apoptosis. 
Several possible relevant comparators in the European setting were identified based on recom-
mendations in guidelines [21-24]. The most common therapies across Europe comprise a combi-
nation of an anthracycline and continuous infusion of cytarabine in the classic ‘3+7’ regimen (i.e. 
3 days of intravenous administration of an anthracycline combined with 7 days of continuous in-
travenous cytarabine as induction chemotherapy), followed by consolidation therapy with interme-
diate or high-dose cytarabine-based chemotherapy, and/or stem cell transplantation, depending 
on the risk group.  
Several anthracyclines at different dosages are used across European countries (e.g., idarubicin). 
Mitoxantrone can be used instead of daunorubicin, and high-dose daunorubicin 90 mg/m2/day can 
be used during induction phase. High-dose daunorubicin has been recommended for example in 
Norway. 
The most relevant comparators for this rapid assessment are as follows (
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Table 3.1): 
 Standard induction and consolidation chemotherapy (cytarabine in combination with 
daunorubicin 60 mg/m2/day during the induction phase). 
 Induction and consolidation chemotherapy, using daunorubicin 90 mg/m2/day (instead of 
60 mg/m2/day) during the induction phase. 
Daunorubicin is a cytotoxic antibiotic (anthracycline family) isolated from Streptomyces coeruleo-
rubidus. Daunorubicin exerts its effects on cancer cells primarily through two mechanisms. Inter-
calation occurs when the drug wedges between the bases of DNA. This blocks DNA from being 
copied (replication) or being translated to make proteins. The drug also inhibits (reduces) the ac-
tivity of an enzyme, topoisomerase type II. This leads to breaks in the genomic DNA. 
Cytarabine is an analogue of pyrimidine, which is part of the genetic material of cells (DNA and 
RNA). In the body, cytarabine takes the place of pyrimidine and interferes with the enzymes in-
volved in the production of new DNA. As a result, cytarabine slows the growth of tumour cells and 
eventually kills them. In DepoCyte, cytarabine is contained in liposomes (small fatty particles), 
from which the medication is slowly released. 
 
PTJA01 - Midostaurin with standard chemotherapy in FLT3 positive acute myeloid leukaemia 
 
Version 1.3, Novermber 2017 EUnetHTA Joint Action 3 WP4 33 
Table 3.1. Features of the intervention and comparators 
 Midostaurin Cytarabine Daunorubicin 
Nonproprietary name Midostaurin Cytarabine Daunorubicin 
Proprietary name Rydapt Several proprietary 
names are used across 
Europe  
Several proprietary 
names are used across 
Europe  
Active substance Midostaurin (PKC412) Cytosine arabinoside 
(ara-C) 
Daunorubicin 
hydrochloride 
Galenic form 25-mg soft capsules IV formulation IV formulation 
ATC code L01XE39 L01BC01 L01DB02 
VNR code N/A Several in use Several in use 
Abbreviations: see List of abbreviations. 
Sources: [17, 25]. 
 
Table 3.2. Administration and dosing of the intervention and comparators 
 Midostaurin Cytarabine Daunorubicin 
Nonproprietary name Midostaurin Cytarabine Daunorubicin 
Administration mode Soft capsules to be taken 
orally 
IV, SC, IM IV 
Description of packaging Capsules are packaged in 
PA/Al/PVC-Al blisters 
Refer to relevant 
country SPC 
Refer to relevant 
country SPC 
Total volume contained in 
packaging for sale 
Packs of 112 capsules of 25 
mg, corresponding to 28 days 
of therapy. A 14-day pack with 
56 capsules might also 
become available in some 
countries. 
Refer to relevant 
country SPC 
Refer to relevant 
country SPC 
Recommended duration 
of treatment 
See Table 3.3 See text below 
table 
See text below table 
Dosing See Table 3.3  According to 
patient´s weight 
and/or body 
surface area 
According to patient´s 
weight and/or body 
surface area 
Contraindications Concomitant administration of 
potent CYP3A4 inducers, e.g., 
rifampicin, St John’s Wort 
(Hypericum perforatum), 
carbamazepine, enzalutamide 
and phenytoin. 
For patients with 
hypersensitivity to the active 
substance or to any of the 
excipients 
Refer to relevant 
country SPC 
Refer to relevant 
country SPC 
For patients with 
hypersensitivity to the 
active substance or to 
any of the excipients or 
to any other 
anthracyclines, older 
patients, patients with 
heart insufficiencies for 
patients previously 
treated with 
anthracyclines and who 
already have reached 
the cumulative maximal 
dose  
Abbreviations: see List of abbreviations. 
Sources: [1, 17, 25]. 
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Recommended duration of treatments 
Midostaurin 
Based on data from the pivotal phase III trial, RATIFY, the median (mean) length of a course of 
therapy is 14 (14) days during induction cycles 1 and 2, 56 (41) days during consolidation and 336 
(262) days during maintenance. Patients receive one or two 28-day cycles of induction therapy 
followed by one to four 28-day cycles of consolidation therapy. During the induction and consoli-
dation cycles, patients achieving CR and not going on to have SCT then receive daily midostaurin 
maintenance monotherapy for up to 12 cycles. 
Induction and consolidation therapy 
According to international guidelines, the most common doses and regimen duration for cytara-
bine and daunorubicin are as follows: 
Induction phase: 
 Cytarabine 100–200 mg/m2/day+daunorubicin (7+3 days) 
 Cytarabine 100–200 mg/m2/day+daunorubicin (5+2 days) 
 Daunorubicin can be administrated as either 60 or 90 mg/m2 day 
 
Consolidation phase: 
 High-dose cytarabine 3 g/m2/day BID 
STC should be considered for patients who are not suitable enough for HDCT. See Table 3.3 for 
more detailed information regarding treatment dosing and duration.  
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Table 3.3. Dosing of midostaurin 
Abbreviations: see List of abbreviations. 
 
[A0020] What are the approved indications of midostaurin? 
Midostaurin is indicated: 
 In combination with standard daunorubicin and cytarabine induction and high-dose cytar-
abine consolidation chemotherapy, and for patients in complete response followed by 
midostaurin single-agent maintenance therapy, for adult patients with newly diagnosed 
AML who are FLT3 mutation positive; 
Method of administration Oral 
Doses  50 mg BID, at approximately 12-h intervals 
Pack size 112 × 25-mg capsules 
A 14-day pack with 56 capsules might also become available in 
some countries 
Dosing frequency Days 8–21 of 28-day chemotherapy cycles (induction and 
consolidation) and daily during midostaurin maintenance 
monotherapy 
Median length of a course of 
treatment (including induction, 
consolidation and maintenance) 
Based on data from the pivotal phase III trial, RATIFY, the 
median (mean) length of a course of therapy was 14 (14) days 
during induction cycles 1 and 2, 56 (41) days during consolidation 
and 336 (262) days during maintenance. Overall, the median 
length of therapy was 42 (136) days. Only 33% of patients 
received maintenance therapy. 
Anticipated average interval 
between courses of treatments 
Patients receive one or two 28-day cycles of induction therapy 
followed by one to four 28-day cycles of consolidation therapy. 
During induction and consolidation cycles, midostaurin is given 
on days 8–21. 
Patients achieving CR and not going on to have SCT then 
receive daily midostaurin maintenance monotherapy for up to 12 
cycles 
Anticipated number of repeat 
courses of treatments 
Not applicable 
Dose adjustments During all three phases of treatment: 
 midostaurin dosing should be interrupted in cases of 
grade 3–4 pulmonary infiltrates for the remainder of the 
cycle and resumed when infiltrate resolves to grade ≤1 
 midostaurin dosing should be interrupted in cases of oth-
er grade 3–4 nonhaematological toxicities considered at 
least possibly related to midostaurin and resumed when 
they have resolved to grade ≤2 
 In cases of QTc interval >470 msec and ≤500 msec, 
midostaurin should be decreased to 50 mg OD for the 
remainder of the cycle and resumed at 50 mg BID in the 
next cycle provided that QTc interval improves to 
≤470 msec at the start of that cycle. Otherwise, midostau-
rin should be continued at 50 mg OD 
 In cases of QTc interval >500 msec, midostaurin should 
be withheld or interrupted for the remainder of the cycle. 
If QTc improves to ≤470 msec just before the next cycle, 
midostaurin should be resumed at the initial dose. If QTc 
interval is not improved in time to start the next cycle, 
midostaurin should not be administered during that cycle. 
Midostaurin can be withheld for as many cycles as nec-
essary until QTc improves 
During maintenance therapy only: 
 In cases of grade 4 neutropenia (ANC <0.5 × 109/L), 
midostaurin should be interrupted until ANC ≥1.0 × 109/L, 
and then resumed at 50 mg BID. If neutropenia (ANC 
<1.0 × 109/L) persists for >2 weeks and is suspected to 
be related to midostaurin, midostaurin should be discon-
tinued 
 In cases of persistent grade 1/2 toxicity that patients 
deem unacceptable, midostaurin can be interrupted for 
up to 28 days 
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 As monotherapy for the treatment of adult patients with aggressive systemic mastocytosis 
(ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or 
mast cell leukaemia (MCL). 
This rapid assessment is limited to the AML indication.  
 
[B0002] What is the claimed benefit of midostaurin in relation to the comparators in AML? 
Midostaurin is the first targeted therapy, and the first tyrosine kinase inhibitor therapy, for patients 
with newly diagnosed FLT3 mutation-positive AML. Midostaurin added to induction and consolida-
tion chemotherapy followed by midostaurin maintenance therapy (in patients not receiving SCT) is 
claimed to extend OS versus standard-of-care treatment. Furthermore, other outcomes such as 
event-free survival (EFS), disease-free survival (DFS), cumulative incidence of relapse (CIR) and 
proportion of patients achieving complete response (CR), after one cycle of induction therapy are 
claimed to support the results and conclusions based on primary outcome. 
 
[B0003] What is the phase of development and implementation of midostaurin and the 
comparator(s)? 
Recommended new text "Midostaurin gained the first regulatory approval worldwide from the US 
Food and Drug Administration (FDA) on 28th April 2017 and from Swissmedic on 4th May 2017 
followed by Health Canada approval on 21st July 2017 and EU approval (EC decision) on 18th 
September 2017. While the FDA and Health Canada approvals were restricted to the induction 
and consolidation phase, the EMA and Swissmedic approvals included induction, consolidation 
and the maintenance phasesThe FDA approval was restricted to the induction and consolidation 
phase. The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
on 20th July 2017. 
Cytarabine and daunorubicin gained regulatory approval for use in AML before CP procedures 
were available.  
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4 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY (CUR) 
 
4.1 Research questions 
Element ID Research question 
A0002 What is AML and the natural course of the disease? What is the impact of FLT3 mutation on 
prognosis and treatment choice?  
A0003 What are the known risk factors for AML? 
A0004 What is the natural course of AML? 
A0005 What are the symptoms and burden of the disease or health condition for the patient? 
A0024 How is AML currently diagnosed according to European published guidelines? 
A0025 How is newly diagnosed AML currently managed in clinical practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
 
4.2 Results 
Overview of the disease or health condition 
 
[A0002] What is AML and natural course of the disease? What is the impact of FLT3 
mutation on prognosis and treatment choice? 
AML is a form of leukaemia (i.e., cancer of the white blood cells) characterised by infiltration of 
proliferative, clonal, abnormally differentiated and occasionally poorly differentiated haematopoiet-
ic cells of myeloid lineage in the bone marrow, blood and other tissues. The prognosis of patients 
with AML varies dramatically because of several prognostic factors: age, performance status, 
cytogenetic and/or molecular genetic alterations, including FLT3, NPM1 and CEBPA. 
The annual crude incidence of AML is 3.7 per 100,000 and the number of new cases per year in 
Europe is estimated at 18,400. AML is the most frequent form of leukaemia, accounting for ap-
proximately 25% of all leukaemias in adults in the Western world. The incidence of AML increases 
sharply with age, ranging from 1.8 cases per 100,000 people aged less than 65 years of age to 
17.6 cases per 100,000 people over 65 years of age. More than half of patients with newly diag-
nosed AML in developed countries are over 65 years of age, with a median age at diagnosis of 
67, and AML is more common in men than in women. [17, 26] 
Genetic alterations in FLT3 in AML 
Among the prognostic molecular alterations, one of the most important factors is the presence of 
FLT3 gene mutations, which occur in approximately 30% of adult patients with AML and have a 
substantial negative impact on prognosis [27]. FLT3 encodes a class III receptor tyrosine kinase 
that comprises five immunoglobulin-like domains, a transmembrane domain, a cytoplasmic jux-
tamembrane domain and two tyrosine kinase domains. FLT3 has a critical role in normal haema-
topoiesis and cellular growth in primitive haematopoietic stem and progenitor cells. Under normal 
conditions, FLT3 is expressed on bone marrow haematopoietic stem cells, but this expression is 
gradually lost as cells differentiate. 
Mutant FLT3 is constitutively activated, which results in the proliferation and survival of leukaemic 
blasts. Two forms of FLT3-activating mutations are identified commonly in blasts from patients 
with AML: internal tandem duplications (ITDs) and point mutations, both of which can occur in the 
juxtamembrane domain or the tyrosine kinase domain. 
FLT3-ITD mutations are observed in 20%–25% of patients with de novo AML and in 30%–35% of 
patients with cytogenetically normal newly diagnosed AML (~30% of all patients with AML). Point 
mutations of the FLT3 protein tyrosine kinase domain (FLT3-TKD mutations) are observed in 5%–
10% of all patients with AML and in 11%–14% of patients with cytogenetically normal AML [28]. 
FLT3-TKD mutations have not been associated with a poor prognosis in some large studies [29]. 
The biology of AML can differ between young and older patients with AML, but not in the subset of 
patients with FLT3 mutations eligible for intensive chemotherapy. The main change in the biology 
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of AML related to age is an increase in complex cytogenetics in older patients, which is not rele-
vant to patients with a FLT mutation. Therefore there are no reasons to expect that the mode of 
action differs between older and younger patients with FLT3-positive AML. Whether midostaurin 
will have the same effect size in older patients as in those included in the RATIFY trial study is 
uncertain. 
Other relevant genetic alterations in AML 
Alterations in NPM1 can also affect the outcome of patients with AML. One-third of patients with 
AML can have a mutation in the NPM1 gene. Results from conventional cytogenetics and from 
NPM1, FLT3 and CEBPA mutational screening are used in routine practice following 2010 ELN 
recommendations [21]. The original intention of the ELN genetic categories was to standardize 
reporting of genetic abnormalities particularly for correlations with clinical characteristics and out-
come. The prognostic impact of many markers is context dependent, with the effect of a given 
abnormality dependent on the presence and/or absence of another. Most recent studies suggest 
that patients with NPM1 mutation and FLT3-ITD with a low (0.5) allelic ratio (FLT3-ITDlow) have a 
similar (favourable) outcome as patients with a NPM1 mutation but no FLT3-ITD; thus, both 
groups are now considered to have a favourable outcome [19, 30-32]. By contrast, patients with 
AML with wild-type NPM1 and FLT3-ITD with a high (0.5) allelic ratio (FLT3-ITDhigh) have a poor 
prognosis and are placed in the adverse-risk group, although the panel acknowledges that the 
natural course of AML with FLT3 mutation might change with the use of FLT3 inhibitors (Table 
4.1) [33]. Prognostic impact of a marker is treatment-dependent and may change with new thera-
pies. 
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Table 4.1. ELN risk stratification by genetics. Standardized reporting for correlation of cy-
togenetic and molecular genetic data in AML with clinical data. 
Risk category  
 
    Genetic abnormality 
Favourable genetic group t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD or with FLT3-ITD low* 
Biallelic mutated CEBPA 
 
Intermediate genetic group Mutated NPM1 and FLT3-ITD high* 
Wild-type NPM1 without FLT3-ITD or with FLT3-ITD low* (without adverse-
risk genetic lesions) 
The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, con-
current adverse-risk gene mutations. 
 
MLLT3-KMT2A 
 
Cytogenetic abnormalities not classified as favourable or adverse** 
 
Adverse genetic group t(6;9)(p23;q34.1); DEK-NUP214 
t(v;11q23.3); KMT2A rearranged 
t(9;22)(q34.1;q11.2); BCR-ABL1 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) 
25 or del(5q); 27; 217/abn(17p) 
 
Complex karyotype*** and monosomal karyotype 
Wild-type NPM1 and FLT3-ITD high* 
Mutated RUNX1  inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
Mutated ASXL1# 
Mutated TP53# 
 
 
* Semiquantitative assessment of FLT3-ITD allelic ratio (using DNA fragment analysis): low allelic ratio (< 0.5);  high allelic 
ratio (≥ 0.5);  
** For most abnormalities, it is not possible to draw firm conclusions regarding their prognostic significance due to a limited 
numbers studied 
*** Three or more chromosome abnormalities in the absence of one of the WHO designated recurring translocations or 
inversions. That is, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3) or t(3;3). This indicate how 
many complex karyotype cases have involvement of chromosome arms 5q, 7q, and 17p 
# These markers should not be used as an adverse prognostic marker if they co-occur with favourable-risk AML subtypes. 
Abbreviations: see List of abbreviations. 
Source: [33] 
 
For patients with AML, the 5-year survival rate is 19%. The mortality rate strongly correlates with 
age, for older patients (60 years and above) the 5-year survival rate is 3%–8%, whereas for 
younger patients (<60 years), the 5-year survival rate can be up to 50% [34]. The CR rate in pa-
tients with FLT3-mutated AML treated with standard first-line induction chemotherapy regimens is 
generally equivalent to that of patients without FLT3 mutations (78% vs. 82%) but median time to 
relapse, DFS, EFS and OS at 5 years are worse [30, 35-37]. For patients with FLT3-mutated AML 
who are <60 years of age and in first remission, the median time to relapse is estimated to be 
approximately 9 months, which is worse than the median 27 months to relapse for patients with 
FLT3 wild-type AML in the same age range [34, 35, 37].  
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[A0003] What are the known risk factors for AML?  
Factors that might increase the risk for AML include [26, 33]: 
 Age. The risk for AML increases with age. AML is most common in adults aged 65 and 
over. 
 Gender. Men are more likely to develop AML than are women. 
 Previous cancer treatment. Patients who have received certain types of chemotherapy 
and radiation therapy might have a greater risk of developing AML. 
 Exposure to certain chemicals, such as benzene, is linked to greater risk for AML. 
 Smoking. 
 Other blood disorders. Patients who have had another blood disorder, such as myelodys-
plasia, polycythaemia vera or thrombocythaemia, are at greater risk of developing AML. 
 
Prognostic factors in AML can be subdivided into those that are related to the patient and those 
that are related to the disease. Patient-associated factors (e.g., increasing age, comorbid conditi-
ons and poor performance status) commonly predict treatment-related early death, whereas dise-
ase-related factors (e.g., white cell count, prior myelodysplastic syndrome or cytotoxic therapy for 
another disorder, and leukaemic-cell genetic changes, including alterations in FLT3) predict re-
sistance to current standard therapy. Alterations in FLT3 and/or in NPM1 can also affect the out-
come of patients with AML. [30, 33, 38] 
The patient’s age or fitness (including performance status and the presence of comorbidities) and 
initial leukocyte count are considered important risk factors. Age or fitness influences survival and 
prognosis, in part related to the fact that initial treatment with intensive chemotherapy might not be 
tolerated by many older and/or less healthy patients. 
History of previous cerebrovascular disease, rheumatological disease, psychiatric disease, and in 
particular, renal disease, have all been shown to affect and increase the risk for all-cause and 
cancer-specific mortality in patients with AML [39]. 
 
[A0004] What is the natural course of AML? 
AML is a heterogeneous haematological malignancy. The term ‘AML’ refers to a group of haema-
topoietic stem cell disorders characterised by the overproduction of immature myeloid stem cells 
(blast cells or ‘blasts’). The percentage of blasts in the bone marrow or blood is particularly im-
portant in defining AML and, according to current World Health Organization (WHO) criteria, the 
blast count for making a diagnosis of AML should generally exceed 20%.[40]  
Current staging and classification systems for the condition recognise that there are two major 
aetiologies of AML: de novo and secondary or iatrogenic AML, resulting from exposure to chemo-
therapy or radiotherapy [41]. This assessment relates to de novo AML only. There are four main 
classifications of AML, namely: AML with recurrent genetic abnormalities; AML with myelodys-
plasia-related changes; AML not otherwise specified (NOS); and therapy-related myeloid neo-
plasms (secondary/iatrogenic AML). The most common subtype is AML NOS, with a 16.8 per 
1,000,000 person-years incidence rate. [42] 
Untreated AML is a fatal disease; median survival is 11–20 weeks, with mortality resulting from 
complications (such as serious infection and haemorrhage) that are associated with the funda-
mental bone marrow failure that defines this leukaemia [43]. Therefore treatment should be initia-
ted as soon as possible, ideally within a matter of days after diagnosis [21]. Despite early inter-
vention after diagnosis, induction chemotherapy might not help all patients achieve remission and 
as many as 50%–70% of those who do achieve remission following chemotherapy relapse within 
3 years [38].  
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Effects of the disease or health condition 
[A0005] What are the symptoms and burden of the disease or health condition for the 
patient? 
The presenting early signs and symptoms of AML can be vague and nonspecific and might inclu-
de fever, fatigue, pain, shortness of breath, cough, bleeding and bruising, pallor and persistent or 
frequent infections, but as many as one-third of patients can be asymptomatic at diagnosis. 
Receiving a diagnosis of AML is traumatic, with little time for patients to adjust to their diagnosis 
before treatment needs to be initiated, and the current standard of care used in management of 
AML can have a significant impact on patient short-term and long-term health-related quality of life 
(HrQoL) [44, 45]. Patients report high rates of fatigue when receiving induction treatment. 
Furthermore, complications of the disease at presentation (such as anaemia, persistent infections 
and bleeding risk) and severe myelosuppression, which is a consequence of both the disease and 
of induction chemotherapy, negatively impact patients. 
Caregivers also face burdens from living with, caring for and supporting a patient with AML, and 
find the period of supporting patients during chemotherapy a time of high burden, describing this 
period as disruptive [46]. Caregivers continue to face burdens across the patient treatment jour-
ney, and there are studies showing that when patients are undergoing SCT, caregivers experi-
ence particular mood disturbances and emotional distress, report a decline in physical functioning, 
general health and vitality, and note a negative impact on social functioning and family care-
giving.[47, 48] 
Current clinical management of the disease or health condition 
 
[A0024] How is AML currently diagnosed according to European published guidelines? 
The procedures used to diagnose and classify AML are:  
 morphologic assessment of bone marrow specimens and blood smears (with ≥20% blasts 
in the bone marrow or peripheral blood being diagnostic of AML); 
 analysis of the expression of cell-surface and cytoplasmic markers; and 
 identification of chromosomal findings, and screening for selected molecular genetic alte-
rations.  
 
Currently, three molecular markers are used as part of standard clinical practice for risk stratifica-
tion [21]:  
 alterations in nucleophosmin-1 (NPM1);  
 alternations in CCAAT/enhancer-binding protein alpha (CEBPA); and  
 alterations in FLT3.  
 
FLT3 mutation testing is required to identify patients for whom midostaurin is relevant. Currently, 
testing for FLT3-ITD is performed in some patients for prognosis. The introduction of midostaurin 
will necessitate the introduction of routine testing for both FLT3-ITD and FLT3-TKD by a validated 
test in a timely manner in all patients eligible to receive intensive chemotherapy. 
Definitive diagnosis of AML requires examination of peripheral blood and bone marrow specimens 
to assess cell morphology and involves cytochemistry, immunophenotyping, cytogenetics and 
molecular genetics to describe the features of AML [26]. 
[A0025] How is newly diagnosed AML currently managed in clinical practice? 
Although AML was incurable 50 years ago, it is now cured in 35%–40% of adult patients who are 
60 years of age or younger and in 5%–15% of patients who are older than 60 years of age [21]. 
Treatment of AML is with curative intent whenever possible. In patients eligible for intensive induc-
tion chemotherapy, treatment comprises a combination of an anthracycline and continuous-
infusion cytarabine in the classic ‘3+7’ regimen (i.e., 3 days of intravenous administration of an 
anthracycline, combined with 7 days of continuous intravenous cytarabine). Current practice is 
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that patients with AML who are older than 60 and otherwise fit should also be treated with stand-
ard induction and consolidation chemotherapy. 
Once complete remission is achieved after intensive therapy, appropriate postremission therapy is 
essential. There is no consensus on a single ‘best’ postremission treatment, but it preferably in-
cludes intermediate or high-dose cytarabine-based chemotherapy, or SCT, depending on the risk 
group. Patients with good-risk AML should receive at least one cycle of intensive cytarabine-
based consolidation chemotherapy. Patients with AML in the intermediate and poor-risk groups 
with an HLA-identical sibling might be candidates for allo-SCT, providing that their age and per-
formance status allow for such treatment. According to clinical expert, allo-SCT can also be rec-
ommended for poor risk groups with an HLA-matched unrelated donor or alternative donors (cord 
blood, haploidentical donor). 
Treatment pathways for the care of patients with AML largely follow current European guidelines 
published by the European Society for Medical Oncology (ESMO) and the ELN. Guidelines have 
also been published by the Italian Society of Hematology, Italian Society of Experimental Hema-
tology and Italian Group for Bone Marrow Transplantation [49] and the National Comprehensive 
Cancer Network (NCCN) [23]. National guidelines are also available for Norway [24]. 
Figure 4.1 summarises the treatment pathway for patients with newly diagnosed AML across Eu-
ropean countries (though deviations from it can be found) [26, 33, 50]. 
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Figure 4.1. Treatment pathway for management of AML. 
 
Target population 
 
[A0007] What is the target population in this assessment? 
This submission relates to patients found to have de novo AML only. The target population for 
midostaurin is adult patients with newly diagnosed AML who are FLT3 mutation positive and are 
suitable for intensive chemotherapy, as per the licence.  
FLT3 mutation testing is required to identify patients for whom midostaurin is relevant. Currently, 
testing for FLT3-ITD is done in some patients for prognosis. The introduction of midostaurin will 
necessitate the introduction of routine testing for both FLT3-ITD and FLT3-TKD by a validated test 
in a timely manner in all patients eligible to receive intensive chemotherapy. 
FLT3-ITD mutations are observed in 20%–25% of patients with de novo AML and in 30%–35% of 
patients with cytogenetically normal newly diagnosed AML (approximately 30% of all adult pa-
tients with AML). FTL3-TKD is observed in approximately 10% of cases. [23] 
[A0023] How many people belong to the target population? 
The estimated target population for midostaurin therapy is calculated based on the incidence of 
AML and the proportion of patients with FLT3 mutation-positive disease who are fit enough to 
receive standard chemotherapy. 
The patient population in the pivotal study was restricted to patients younger than 60 years of age. 
This reflects the standard of care at the time that the pivotal study was initiated, i.e., at that stage, 
patients older than 60 years of age were deemed ineligible for standard induction and consolida-
tion chemotherapy. Current practice is that all patients with AML who are fit, even if they are older 
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than 60 years, should be treated with standard induction and consolidation chemotherapy; thus 
the target population includes adults over 18 years with no upper age limit. 
The estimated incidence of AML is 3.4–3.7 per 100,000 for the EU overall. Approximately 60% of 
patients receive intensive chemotherapy according to a Swedish registry study [51]. FLT3 muta-
tions are estimated to occur in approximately 30% of patients with AML [52, 53]. Given that the 
testing for FLT-3 mutation is not yet an established practice, there is no sufficient evidence to 
support an estimate proportion of patients for eligible for midostaurin treatment among all those 
diagnosed with de novo AML. The exact prevalence of FLT3 mutations across different age 
groups of patients with AML has not been established.  
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5 CLINICAL EFFECTIVENESS (EFF) 
5.1 Research questions 
Element ID Research question 
D0001 What is the expected effect of midostaurin on overall survival? 
This issue will cover the following outcomes: 
 OS 
 OS, censoring participants who receive SCT at the time of the transplant 
D0006 What is the effect of midostaurin on disease progression, treatment response and relapse 
rate? 
This issue will cover the following outcomes: 
 Event-free survival (EFS) 
 Disease-free survival (DFS) 
 Complete response (CR) 
 Relapse rate 
D0012 What is the effect of midostaurin on generic health-related quality of life? 
D0013 What is the effect of midostaurin on disease-specific quality of life? 
 
5.2 Results 
Included studies 
The assessment of clinical effectiveness was based on three studies: the RATIFY, IIT and UK 
NCRI AML17 trials. RATIFY was the placebo-controlled RCT most relevant to this assessment, 
and most of the results in this domain are based on the results of the RATIFY trial. The data 
summarised here are based on a data cut-off of 1st April 2015 (based an on interim report in April 
2016).  
The on-going single-arm phase II IIT trial provided supporting data on older patients. These data 
were mainly used in evaluating clinical effectiveness in an older population. 
The UK NCRI AML17 trial compared chemotherapy with daunorubicin 60 mg/m2 to high-dose 
daunorubicin used in induction. The results of the subgroup analysis of this study were applied 
only on the indirect comparisons related to OS. Key features of these studies are summarised 
below. 
 
RATIFY trial 
Detailed features of the RATIFY trial are provided in the MAH submission file and are summarised 
here.  
RATIFY was a multicentre, phase III, randomised, double-blind, placebo-controlled trial assessing 
midostaurin in combination with standard chemotherapy followed by midostaurin monotherapy 
versus standard chemotherapy alone in patients with FLT3 mutation-positive AML. Patients were 
stratified by FLT3 mutation subtype (TKD vs. ITD high allelic mutation fraction [≥0.7] vs. ITD low 
mutation fraction [<0.7]) Table A2 in Appendix 1 provides further details of this study. 
The study included patients with newly diagnosed FLT3 mutation-positive (FLT3-ITD or FLT3-
TKD) AML aged ≥18 and <60 years. Patients with therapy-related AML, those with raised total 
bilirubin and/or with symptomatic congestive heart failure were excluded, as were patients who 
had received prior chemotherapy for myelodysplasia. The total number of patients was 717. Base-
line characteristics of patients are shown in Table 5.1. Patient disposition is presented in Figure 
5.2. 
Table 5.1. Baseline characteristics of patients in the RATIFY trial 
Characteristic Midostaurin 
(n=360) 
Placebo 
(n=357) 
Total 
(n=717) 
Age, years 
Mean (SD) 
Median (range) 
 
44.9 (10.4) 
47.0 (19–59) 
 
45.5 (10.8) 
48.0 (18–60) 
 
45.2 (10.6) 
47.0 (18–60) 
Male, n (%) 174 (48.3) 145 (40.6) 319 (44.5) 
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BSA, mean (SD) m2 2.0 (0.29) 1.9 (0.28) 1.9 (0.28) 
ECOG/Zubrod performance status, n (%) 
0 164 (45.6) 142 (39.8) 306 (42.7) 
1 159 (44.2) 168 (47.1) 327 (45.6) 
2 29 (8.1) 36 (10.1) 65 (9.1) 
3 6 (1.7) 9 (2.5) 15 (2.1) 
4 2 (0.6) 2 (0.6) 4 (0.6) 
Region, n (%)    
North America 121 (33.6) 115 (32.2) 236 (32.9) 
Non-North America 239 (66.4) 242 (67.8) 481 (67.1) 
FLT3 mutation status, n (%) 
TKD 83 (23.1) 80 (22.4) 163 (22.7) 
ITD (includes patients with both TKD and ITD) 276 (76.7) 274 (76.8) 550 (76.7) 
ITD Allelic ratio <0.7 164 (45.6) 165 (46.2) 329 (45.9) 
ITD Allelic ratio ≥0.7 112 (31.1) 109 (30.5) 221 (30.8) 
No FLT3 gene mutation 1 (0.3) 3 (0.8) 4 (0.6) 
Patients with prior MDS 14 (3.9) 16 (4.5) 30 (4.2) 
Abbreviations: see List of abbreviations. 
 
The trial comprised three treatment phases (Figure 5.1): 
 Induction (1–2 cycles): cytarabine+daunorubicin+midostaurin OR placebo  
 Consolidation (1–4 cycles): high-dose cytarabine+midostaurin OR placebo 
 Maintenance (up to 12 cycles): midostaurin monotherapy OR placebo. 
Receipt of SCT was not part of the RATIFY study protocol. Patients who received SCT did so 
according to the investigator’s decision and, thus, this could occur in CR1 (i.e., first remission), 
after CR1 (i.e., after patients had relapsed following achieving their first remission) or for patients 
who were treatment failures after they stopped treatment during induction. SCT was considered 
the reason for treatment discontinuation only for SCTs performed for patients in CR1 and if the 
patient underwent SCT ≤2 months after discontinuing treatment. Patients undergoing SCT >2 
months after stopping study treatment are likely to have been discontinued from the study for 
other reasons, and would have then progressed to SCT. Similarly, patients undergoing SCT after 
relapse or after treatment failure would have received other therapies (off study) to achieve CR 
before SCT. 
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Figure 5.1. RATIFY trial study design.  
 
Abbreviations: see List of abbreviations. *Central randomisation within three strata: FLT3-TKD, FLT3-ITD with allelic 
ratio ≥0.7; FLT3-ITD with allelic ratio <0.7 [17]. 
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Figure 5.2. Patient disposition in the RATIFY trial.  
Abbreviations: see List of abbreviations. 
 
 
IIT trial (AMLSG 16-10) 
The IIT in an on-going single-arm study evaluating the efficacy and safety of midostaurin added to 
chemotherapy (induction followed by consolidation) followed by midostaurin monotherapy in pa-
tients with newly diagnosed FLT3-ITD-positive AML. The primary objective was to compare out-
comes for patients aged 18–60 years with those aged 61–70 years [17]. The total number of pa-
tients was 145 at the time of the interim CSR, with a data cut-off on 31-Dec-2015. Baseline char-
acteristics of IIT trial are shown in Table 5.2. 
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Table 5.2. Baseline characteristics of patients in IIT trial 
Demographic variables  All patients 
(n=145) 
Patients ≤60 years  
(n=99) 
Patients >60 years  
(n=46) 
Age, years 
Mean (SD) 53 (11) 48 (9) 65 (3) 
Median (range) 54 (20–69) 50 (20–60) 65 (61–69) 
Sex, n (%) 
Men 61 (42) 38 (38) 23 (50) 
Women 84 (58) 61 (62) 23 (50) 
ECOG performance status, n (%) 
0 55 (38) 41 (42) 14 (30) 
1 76 (53) 47 (48) 29 (63) 
2 13 (9) 10 (10) 3 (7) 
FLT3 mutation status, n (%) 
FLT3-TKD 3 (2) 2 (2) 1 (2) 
FLT3-ITD ratio ≤0.50 69 (48) 47 (47) 22 (48) 
FLT3-ITD ratio >0.50 76 (52) 52 (53) 24 (52) 
Abbreviations: see List of abbreviations. 
 
The primary endpoint was EFS after 2 years (defined as the time between study entry and any of 
the following: death during induction therapy, refractory disease or PR after response-adapted 
induction therapy, relapse and death in CR). RFS was defined as the time to relapse or death in 
CR for patients achieving a CR. Other endpoints included OS and CR rates. 
Treatment comprised induction and consolidation followed by midostaurin monotherapy given for 
up to 1 year. Induction therapy comprised daunorubicin 60 mg/m² (days 1–3), cytarabine 
200 mg/m² (continuously, days 1–7) and midostaurin 50 mg BID (from day 8 to 48 h before start 
of the next treatment cycle). The design of the study is characterised in Figure 5.3. 
 
  
Figure 5.3. Study design of IIT AMLSG 16-10.  
 
Abbreviations: see List of abbreviations. 
Source: [17] 
 
UK AML17, subgroup analysis of patients with FLT3-ITD mutated AML 
In this study, 1206 patients were randomised in 1:1 to daunorubicin 90 mg/m2 or 60 mg/m2 in 
course 1, then 50 mg/m2 in course 2 with cytarabine 100 mg/m2 12-h days 1–10 (course 1) and 
days 1–8 (course 2). The median age was 53 years (16–72); 54% were male; 84% had de novo 
AML, 10% secondary and 6% high-risk MDS; median presenting white blood cell count was 
8.5(0.3–430)x109 cells/L; 10% had favourable cytogenetics, 72% intermediate and 18% adverse. 
[11]  
Originally, the objectives of this study were to [10]:  
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1. Compare the overall efficacy of daunorubicin 90 mg/m2 versus 60 mg/m2 for induction in 
AML, based on findings of a RCT. 
2. Compare the overall safety and toxicity of daunorubicin 90 mg/m2 versus 60 mg/m2 for in-
duction in AML. 
3. Compare daunorubicin 90 mg/m2 versus 60 mg/m2 for induction in AML in various sub-
groups. 
 
In the overall study results, FLT3-ITD mutation status showed a significant interaction with treat-
ment group in an explorative subgroup analysis. In this assessment, we considered subgroup 
analysis with patients with FLT3-ITD mutated AML (n=200), and performed an indirect compari-
son of midostaurin and daunorubicin 90 mg/m2 in induction therapy based on subgroup analysis 
results concerning OS published in [11]. Only the results for OS were included in the indirect 
comparison, because the results from the other outcomes in this subgroup were not available. 
Furthermore, details of the baseline characteristics of sub-group of patients with FLT3-ITD mutat-
ed AML are not available for assessing the similarity of the patient groups compared in the indi-
rect analysis. Baseline characteristics of the whole study population can be found in [10].  Despite 
these uncertainties, indirect comparison was performed, because high-dose daunorubicin was 
considered a relevant comparator to midostaurin. Further details of this study are provided in Ap-
pendix 1 and Table A3. 
Mortality 
[D0001] What is the expected effect of midostaurin on overall survival? 
 
RATIFY trial 
In the RATIFY trial, the risk of death was reduced by 23% during follow-up for midostaurin versus 
placebo (HR 0.77 [95% CI 0.63–0.95]; p=0.0078). The proportion of patients alive for midostaurin 
versus placebo at 1 and 5 years were [17]: 
 1 year – 76% (95% CI: 0.72–0.81) versus 68% (95% CI: 0.62–0.72), respectively 
 5 years – 51% (95% CI: 0.45–0.56) versus 43% (95% CI: 0.38–0.49), respectively. 
During the RATIFY study, 57% of the patients received SCT, which exceeded the prestudy esti-
mated rate of 15%. Overall SCT rates were 59.4% and 55.2% in the midostaurin and placebo 
groups, respectively, with approximately one-fifth of patients (22.2% and 19.3%, respectively) 
receiving SCT during the first CR. Similar to the OS results, results for OS censored at SCT 
showed a reduced risk of death for midostaurin over placebo (HR 0.75 [95% CI: 0.54–1.03]; 
p=0.0373). OS results and results for OS censored at SCT are summarised in Table 5.3 and in 
Figure 5.4 and Figure 5.5.  
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Table 5.3. Summary of OS results from the RATIFY trial 
Endpoint Midostaurin 
(n=360) 
Placebo 
(n=357) 
HR (95% CI), p value (one-sided) 
Overall survival 
Median, months 74.7 25.6 HR 0.774 (0.629–0.953); p=0.0078 
1 year, % 76 68  
3 year, % 54 47  
5 year, % 51 43  
Overall survival, censored at SCT 
Median, months NE NE HR 0.749 (0.544–1.031); p=0.0373 
1 year, % 82 70  
3 year, % 65 58  
5 year, % 64 56  
Abbreviations: see List of abbreviations. 
 
 
Figure 5.4. Overall survival, noncensored at the time of SCT.  
 
Abbreviations: see List of abbreviations. 
Source: [17] 
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Figure 5.5. Kaplan–Meier curve for overall survival, censored at the time of SCT. 
Abbreviations: see List of abbreviations. 
Source: [17] 
 
IIT trial 
The following OS data were available for a median follow-up of 25.2 months (Table 5.4). The pro-
portion of younger patients (≤60 years) alive at 2-year follow-up was 53.7%, whereas the propor-
tion of older patients (>60 years) was 45.2%. The median survival rates were 28.5 months and 
15.5 months, respectively. 
Comparison of efficacy in the RATIFY and ITT studies was included in the MAH submission file as 
a confidential appendix. Similarly, comparison of efficacy of patients over 60 years of age from the 
ITT trial with historical controls was also provided as a confidential appendix. Consequently, fur-
ther details of these results cannot be provided here. 
 
Table 5.4. OS results for the IIT trial 
Endpoint All patients 
(n=145) 
Aged ≤60 years 
(n=99) 
Aged >60 years 
(n=46) 
OS 
Median OS, months 24.7 28.5 15.5 
2-year OS, %  51.0 53.7 45.2 
Abbreviations: see List of abbreviations. 
 
Indirect comparison of midostaurin and high-dose daunorubicin 
Chemotherapy with high-dose daunorubicin (90 mg/m2) used in induction was included as a com-
parator in this assessment, but direct evidence was not available. Comparison of midostaurin with 
standard induction and consolidation chemotherapy versus high-dose daunorubicin used in induc-
tion was performed indirectly using the Bucher method [54, 55]. Results are shown in Table 5.5. 
Indirect results comparing midostaurin with high-dose daunorubicin used in induction showed no 
difference between the treatments in terms of OS. Consequently, there is no evidence that mi-
dostaurin treatment would be more beneficial than high-dose daunorubicin used in induction, or 
vice versa. Several limitations apply to this indirect comparison, which are discussed in Section 8. 
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Table 5.5. Results of the indirect comparison of the RATIFY and UK NCRI AML17 trials 
 Comparison OS (95% CI) Reference 
RATIFY 
 Full analysis set 
 n=717 
Midostaurin/DA 60 mg/m2 vs. 
placebo/DA 60 mg/m2 
HR 0.774 
(0.629–0.953) 
[17] 
UK NCRI AML17 
 subgroup of patients 
with FLT3-ITD mutation 
 n=200 
DA 90 mg/m2 vs. 60 mg/m2 
HR 0.65 (0.43–
0.96) 
[11] 
Indirect comparison 
 Bucher method 
DA 90 mg/m2 vs. midostau-
rin/DA 60 mg/m2 
HR 0.84 (0.54–
1.31) 
[18] 
Abbreviations: see List of abbreviations. DA 60 mg/m2=daunorubicin 60 mg/m2 used in induction therapy; DA 90 
mg/m2=high-dose daunorubicin (90 mg/m2) in induction therapy. 
 
Subgroup analyses of OS 
MAH presented prespecified subgroup analyses in the submission file (Figure 5.6). Subgroups 
assessed included breakdown by FLT3 randomisation/mutation/subtype, gender, region, race, 
prior MDS, WBC count and cytogenetics. The indication for midostaurin is for patients with newly 
diagnosed AML. Patients who had received prior treatment for MDS were not relevant to this as-
sessment. A difference in OS was observed for men versus women.  
A post-hoc subgroup analysis of data from RATIFY was performed regarding NPM1 status. Post 
data base lock, data regarding NPM1 status were available for 563 patients, 294 in the midostau-
rin group and 269 in the placebo group; of the midostaurin group, 55% had mutated NPM1 as did 
60% of the placebo group. Furthermore, OS results in patients undergoing SCT and not undergo-
ing SCT were included in the MAH submission. Results of these subgroup analyses are present-
ed in  
 
Table 5.6. 
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Figure 5.6. Prespecified subgroup analyses for OS. 
Abbreviations: see List of abbreviations. 
Source: [17]. 
 
Table 5.6. Results of the post-hoc subgroup analyses (RATIFY trial) 
Endpoint Midostaurin 
(n=360) 
Placebo 
(n=357) 
HR (95% CI), p value (one-sided) 
Overall survival in patients undergoing SCT 
n 214 197  
Median, months 74.7 35.9 HR 0.780 (0.593–1.026); p=0.0376 
1 year, % 84 77  
3 year, % 57 50  
5 year, % 52 45  
Overall survival in patients not undergoing SCT 
n 146 160  
Median, months 31.7 14.7 HR 0.798 (0.580–1.098); p=0.0822 
1 year, % 66 54  
3 year, % 50 42  
5 year, % 49 41  
Overall survival in patients with NPM1 mutation 
n NA NA  
Median, months NA NA HR 0.72 (0.52–1.01) 
Overall survival in patients with NPM1 wild type 
n NA NA  
Median, months NA NA HR 0.74 (0.54–1.03) 
Abbreviations: see List of abbreviations. 
Source: [17]. 
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Morbidity 
[D0006] What is the effect of midostaurin on disease progression, treatment response and 
relapse rate? 
RATIFY trial 
MAH presented the results for complete response rate, EFS, DFS and CIR of the RATIFY trial in 
the submission file. Results censored at SCT were also provided for EFS, DFS and CIR. Further-
more, DFS results were provided from first CR, censored from SCT, from the start of maintenance 
and censored at the end of maintenance, and from the end of maintenance. The results are sum-
marised in Table 5.7 and in Figure 5.7 and Figure 5.8. Results for CRR (overall, %) are based on 
the alternative definition for CR rate and includes all CRs occurring during induction. Using the 
protocol-specified definition of a CR (a CR within 60 days of treatment initiation), the proportion of 
patients in the midostaurin arm achieving CR was 58.9% versus 53.5% for placebo (p=0.073). 
PTJA01 - Midostaurin with standard chemotherapy in FLT3 positive acute myeloid leukaemia 
 
Version 1.3, Novermber 2017 EUnetHTA Joint Action 3 WP4 56 
 
Table 5.7. Summary of RATIFY trial results for complete response rate, event-free survival, 
disease-free survival and cumulative incidence of relapse 
Endpoint Midostaurin 
(n=360) 
Placebo 
(n=357) 
HR (95% CI), p value (one-sided) 
Complete response rate, % 
Overall, % 65.0 58.0 p=0.027 (one-sided, CMH) 
Induction: end of 
cycle 1 
51.7 43.1  
Induction: end of 
cycle 2 
13.3 14.8  
Event-free survival 
Median, months 10.2 5.6 HR 0.728 (0.613–0.866); p=0.0001 
1 year, % 47 33  
3 year, % 32 23  
5 year, % 31 21  
Event-free survival, censored at SCT 
Median, months 10.1 5.6 HR 0.762 (0633–0.918); p=0.0019 
1 year, % 46 31  
3 year, % 29 23  
5 year, % 28 21  
Disease-free survival from first CR 
Median, months 28.1 14.1 HR 0.663 (0.516–0.853); p=0.0006 
1 year, % 70 54  
3 year, % 49 38  
5 year, % 48 36  
Disease-free survival from first CR, censored at SCT 
Median, months 20.7 14.5 HR 0.721 (0.536–0.970); p=0.0150 
1 year, % 68 53  
3 year, % 44 39  
5 year, % 44 37  
Disease-free survival from start of maintenance and censored at end of maintenance 
n 115 79  
Median, months NE NE HR 0.714 (0.430–1.184); p=0.0950 
6 months, % 79 75  
10 months, % 72 67  
Disease-free survival from end of maintenance 
n 96 73  
Median, months NE NE HR 1.369 (0.604–3.102); p=0.7753 
1 year, % 77 91  
3 year, % 75 80  
5 year, % 75 72  
Cumulative incidence of relapse 
n 234 207  
    Median, months NE 17.6 HR 0.676 (0.515–0.888); p=0.0023 
Cumulative incidence of relapse – censored at SCT 
    Median, months 21.5 14.8 HR 0.761 (0.561–1.031); p=0.0387 
Abbreviations: see List of abbreviations. 
Source: [17] 
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Figure 5.7. Disease-free survival, noncensored at the time of SCT.  
Abbreviations: see List of abbreviations. 
Source: [17] 
 
 
 
Figure 5.8. Cumulative incidence of relapse, noncensored at the time of SCT.  
Abbreviations: see List of abbreviations. 
Source: [17] 
 
 
IIT trial 
MAH presented results for complete response rate, EFS, RFS and CIR of the IIT trial in the sub-
mission file. Results were provided for the full population and separately for patients aged ≤60 
and >60 years. The results were based on interim CSR, with a data cut-ff of 31-Dec-2015. The 
results are summarised in Table 5.8. 
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Table 5.8. Summary of single-arm IIT trial results for complete response, event-free surviv-
al, relapse-free survival and cumulative incidence of relapse 
Endpoint All patients 
(n=145) 
Aged ≤60 years 
(n=99) 
Aged >60 years 
(n=46) 
CR, n (%) 107 (74) 76 (77) 31 (67) 
EFS 
Median EFS, months 10.7 13.8 9.3 
2-year EFS, % 34.6 38.2 27.1 
RFS 
Median RFS, months 21.2 25.9 18.7 
2-year RFS, % 46.7 51.3 36.6 
Cumulative incidence of relapse, % 27.8 22.2 40.0 
Abbreviations: see List of abbreviations. 
Source: [17] 
 
An exploratory analysis comparing IIT trial data with historical controls was provided in the MAH 
submission file. Kaplan–Meier curves for RFS in patients treated with midostaurin and with histor-
ical controls aged 18–60 and 60–70 years are shown in Figure 5.9. 
 
 
Figure 5.9. RFS in patients treated with midostaurin in the IIT and historical controls: a) 
patients aged 18–60 years; b) >60–70 years.  
Abbreviations: see List of abbreviations. 
Source: [17] 
 
Health-related quality of life 
[D0012] What is the effect of midostaurin on generic health-related quality of life? 
There are no results available on the effect of midostaurin on the generic HrQoL, because this 
has not been investigated in the studies completed to date. 
[D0013] What is the effect of midostaurin on disease-specific quality of life? 
There are no results available on the effect of midostaurin on the disease-specific quality of life, 
because this has not been investigated in the studies completed to date. 
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6 SAFETY (SAF) 
 
6.1 Research questions 
Element ID Research question 
C0008 How safe is midostaurin in relation to the comparators?  
The following outcomes will be covered in this issue:  
 AEs (adverse events) 
 serious AEs (SAE) 
 discontinuation because of AE 
 death as SAE 
 AEs of special interest 
 grade ≥3 AEs 
Dose and time dependencies of harms and patient groups that are most likely to be 
harmed will be covered under this issue. 
 
6.2 Results 
Included studies 
This section is based on RATIFY and IIT trial results. Please see above (EFF domain) for details. 
The data were extracted from the MAH submission file [17] and the update as per PKC412A2301 
CSR Amendment 1 provided by MAH at later stage. 
 
Patient safety 
 
[C0008] How safe is midostaurin in relation to the comparators? 
RATIFY trial 
Adverse events 
A summary of the AEs recorded in the RATIFY study is provided in Table 6.1 according to the 
MAH submission. There were 36 deaths on-treatment (i.e., within 30 days of the last treatment; 15 
and 21 in the midostaurin and placebo arms, respectively). Approximately 50% of the patients in 
both groups experienced a grade 3-4 SAE and approximately 75% of patients in both groups re-
ported at least one grade 3–4 AE considered to be related to treatment. Of the patients, 6.7% in 
the midostaurin group and 5.1% in the placebo discontinued therapy because of grade 3–4 AEs. 
Haematological AEs were the most frequently reported AEs in both treatment groups, with ≥89% 
of patients in both groups reporting grade 3–4 thrombocytopaenia, anaemia and neutropaenia 
(Table 6.1). The most frequent nonhaematological grade 3–4 AEs in the midostaurin group were 
device-related infections (15.7%), diarrhoea (15.4%) and exfoliative dermatitis (13.6%), and in the 
placebo arm were hypokalaemia (17.0%), diarrhoea (15.2%) and pneumonia (14.0%). In addition 
to the AEs listed in Table 6.1, QTc prolongation has been observed in patients receiving 
midostaurin. 
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Table 6.1. Summary of AEs in RATIFY, including grade 3–4 AEs reported in ≥10% of pa-
tients receiving midostaurin regardless of relationship to study drug: overall and during 
maintenance therapy 
System organ class AEs 
Overall Maintenance therapy only 
Midostaurin 
(n=345) 
Placebo 
(n=335) 
Midostaurin 
 (n=120) 
Placebo 
(n=85) 
Death, n (%) 15 (4.3) 21 (6.3) 0 1 (1.2) 
Grade 3–4 SAEs, n (%) 169 (49.0) 164 (49.0)  
16 (13.3) 
 
10 (11.8) 
Grade 3–4 AEs, n (%) 344 (99.7) 335 (100.0) 49 (40.8) 40 (47.1) 
Grade 3–4 AEs suspected to 
be related to treatment, n (%) 
269 (78.0) 252 (75.2) NR NR 
Withdrawal because of grade 
3–4 AEs, n (%) 
23 (6.7) 17 (5.1) 4(3.3) 4(4.7) 
Grade 3–4 AEs reported in ≥10% of patients receiving midostaurin, n (%) 
Thrombocytopaenia 337 (97.7) 326 (97.3) 3 (2.5) 13 (15.3) 
Neutropaenia 329 (95.4) 327 (97.6) 10 (8.3) 8 (9.4) 
Anaemia 322 (93.3) 298 (89.0) 1 (0.8) 0 
Febrile neutropaenia 288 (83.5) 278 (83.0) 1 (0.8) 0 
Leucopaenia 93 (27.0) 101 (30.1) 3 (2.5) 0 
Lymphopaenia 69 (20.0) 76 (22.7) 8 (6.7) 2 (2.4) 
Device-related infection 54 (15.7) 33 (9.9) 0 0 
Diarrhoea 53 (15.4) 51 (15.2) 1 (0.8) 2 (2.4) 
Hypokalaemia 48 (13.9) 57 (17.0) 0 1 (1.2) 
Dermatitis exfoliative 47 (13.6) 25 (7.5) 1 (0.8) 0 
Pneumonia 45 (13.0) 47 (14.0) 0 0 
Increased ALT  45 (13.0) 32 (9.6) 5 (4.2) 4 (4.7) 
Abbreviations: see List of abbreviations. 
Source: [17] 
 
Serious AEs 
Almost half of the patients (49% and 49% of patients in the midostaurin and placebo arms, re-
spectively) experienced at least one grade 3-4 SAE and over half of these were suspected to be 
related to study treatment (Table 6.2). Febrile neutropaenia, decreased neutrophil count, decrea-
sed platelet count, device-related infection and pneumonia were the most frequently occurring 
SAEs in the midostaurin group, each with incidences >5%. Of those patients receiving midostau-
rin maintenance monotherapy, 12% experienced a SAE (compared with 11% for placebo). 
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Table 6.2. Grade 3-4 SAEs reported in ≥ 2% of patients in the midostaurin group regardless 
of relationship to midostaurin or placebo in the RATIFY trial  
SAE, n (%) 
Overall Maintenance therapy only 
Midostaurin 
(n=345) 
Placebo 
(n=335) 
Midostaurin 
(n=120) 
Placebo 
(n=85) 
Any event 169 (49.0) 164 (49.0) 16 (13.3) 10 (10.8) 
Febrile neutropaenia 53 (15.4) 53 (15.8)   
Neutrophil count 
decreased 
29 (8.4) 33 (9.9) 3 (2.5) 1 (1.2) 
Device-related 
infection 
23 (6.7) 12 (3.6) — — 
Platelet count 
decreased 
23 (6.7) 28 (8.4) 0 2 (2.4) 
Pneumonia 23 (6.7) 23 (6.9) 0 0 
Sepsis 16 (4.6) 14 (4.2) — — 
Haemoglobin 
decreased 
12 (3.5) 9 (2.7) 0 0 
Hypotension 12 (3.5) 1 (0.3) 0 0 
Neutropenic infection 12 (3.5) 6 (1.8) — — 
Pneumonitis 11 (3.2) 8 (2.4) — 1 (1.2) 
Dermatitis exfoliative 10 (2.9) 1 (0.3) — — 
Neutropaenic sepsis 10 (2.9) 1 (0.3) — — 
AST increased 9 (2.6) 1 (0.3) 1 (0.8) 0 
ALT increased 8 (2.3) 3 (0.9) 0 0 
Hypokalaemia 8 (2.3) 3 (0.9) — — 
Infection 8 (2.3) 3 (0.9) 1 (0.8) 0 
Leucopoenia 8 (2.3) 7 (2.1) 1 (0.8) 0 
Renal failure 8 (2.3) 2 (0.6) — — 
Acute respiratory  
distress syndrome 
7 (2.0) 3 (0.9) — — 
Colitis 7 (2.0) 9 (2.7) 0 0 
Hypoxia 7 (2.0) 0 — — 
Abbreviations: see List of abbreviations. 
Source: [17] 
 
Discontinuation because of AEs 
Overall, 23(6.7%) patients in the midostaurin group and 17 (5.1%) patients in the placebo group 
discontinued therapy because of grade 3–4 AEs (Table 6.3). The events leading to discontinua-
tion in more than one patient were dermatitis exfoliative, increased ALT, increased AST, de-
creased neutrophil count, and renal failure in the midostaurin group and febrile neutropaenia, 
decreased neutrophil count and decrease platelet count in the placebo group. In both treatment 
groups, four patients discontinued treatment because of AEs during the maintenance therapy. 
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Table 6.3. Grade 3–4 AEs leading to treatment discontinuation in RATIFY in at least 1 pa-
tients in the midostaurin group 
 
Grade 3–4 AEs leading to 
discontinuation, n (%) 
Midostaurin 
(n=345) 
Placebo 
(n=335) 
Overall incidence 23 (6.7) 17 (5.1) 
Dermatitis exfoliative 4 (1.2) 0 
ALT increased 3 (0.9) 1 (0.3) 
AST increased 2 (0.6) 0 
Neutrophil count decreased 2 (0.6) 2 (0.6) 
Renal failure 2 (0.6) 0 
Atrioventricular block 1 (0.3) 0 
Central nervous system leukaemia 1 (0.3) 0 
Cervical vertebral fracture 1 (0.3) 0 
Chloroma 1 (0.3) 0 
Device-related infection 1 (0.3) 0 
Febrile neutropaenia 1 (0.3) 3 (0.9) 
Haemoglobin decreased 1 (0.3) 0 
Hypercholesterolaemia 1 (0.3) 0 
Hypertriglyceridaemia 1 (0.3) 0 
Jaundice 1 (0.3) 0 
Jaw fracture 1 (0.3) 0 
Myocardial ischaemia 1 (0.3) 0 
Platelet count decreased 1 (0.3) 4 (1.2) 
Pneumonitis 1 (0.3) 1 (0.3) 
Pregnancy 1 (0.3) 0 
Pulmonary haemorrhage 1 (0.3) 0 
Rib fracture 1 (0.3) 0 
Staphylococcal infection 1 (0.3) 0 
Troponin T increased 1 (0.3) 1 (0.3) 
Abbreviations: see List of abbreviations. 
Source: [17] 
 
Death as SAE 
According to MAH submission, on-treatment deaths (those occurring within 30 days of last dose 
of study drug) occurred in 15 (4.3%) and 21 (6.3%) patients in the midostaurin and placebo arms, 
respectively. Three deaths resulted from AML/disease progression (one for midostaurin and two 
for placebo) and most deaths resulted from infections.  
Most deaths occurred during the induction phase (14 [4.1%] patients in the midostaurin group and 
11 [3.3%] patients in the placebo group). Nine and seven deaths (2.6% and 2.1%) in the 
midostaurin and placebo groups, respectively, were suspected to be related to the study medica-
tion. Causes in the midostaurin group included sepsis in two patients, and multiorgan failure, in-
fectious colitis, acute respiratory failure, colitis, myocardial infarction, neutropaenic sepsis, pulmo-
nary haemorrhage and septic shock in one patient each. 
IIT trial 
The safety data presented here are fully based on the MAH submission [17], in which data from 
the IIT trial were reported for the initial analysis, which included 145 patients with a median follow-
up of 25.2 months and a comparison of the safety profile of midostaurin in patients ≤60 years and 
61–70-years old. AEs, AEs of grade 3–4 and treatment-related AEs are summarised in Table 6.4 
for the all the patients and separately for patients aged 18–60 and over 60 years.  Furthermore, a 
summary of treatment-related serious AEs and any AEs leading to treatment discontinuation in 
more than 1 patient is provided in Table 6.5. 
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Table 6.4. Summary of the incidence of AEs and incidence of grade ≥3 treatment-related 
AEs occurring in ≥5% of patients in the IIT 
Endpoint 
All patients 
(n=144) 
Aged ≤60 years 
(n=98) 
Aged >60 years 
(n=46) 
Any AE 144 (100) 98 (100) 46 (100) 
Deaths (during study treatment 
and 30-day follow-up period) 
16 (11) 6 (6) 10 (22) 
Other serious AEs 94 (65) 61 (62) 33 (72) 
Withdrawn from Rydapt® 
treatment because of AEs 
41 (28) 26 (27) 15 (33) 
Treatment-related AEs  135 (94) 93 (95) 42 (91) 
Nonhaematological treatment-related grade ≥3 AEs reported in ≥5% of patients overall or in either 
age group, n (%) 
Nausea 17 (12) 8 (8) 9 (20) 
Lung infection 14 (10) 7 (7) 7 (15) 
QT prolongation 10 (7) 4 (4) 6 (13) 
Sepsis 10 (7) 5 (5) 5 (11) 
Device-related infection 8 (6) 6 (6) 2 (4) 
Diarrhoea 9 (6) 5 (5) 4 (9) 
Vomiting 7 (5) 5 (5) 2 (4) 
Hypokalaemia 7 (5) 5 (5) 2 (4) 
Gastrointestinal inflammation 7 (5) 6 (6) 1 (2) 
ALT elevation 7 (5) 5 (5) 2 (4) 
Hepatobiliary disorder 5 (3) 5 (5) 0 
Hypertension 4 (3) 1 (1) 3 (7) 
Haematological treatment-related grade ≥3 AEs reported in ≥5% of patients, n (%) 
Decreased platelet count 80 (56) 55 (56) 25 (54) 
Decreased haemoglobin 66 (46) 42 (43) 24 (52) 
Leucopoenia 71 (49) 48 (49) 23 (50) 
Neutropaenia 44 (31) 32 (33) 12 (26) 
Febrile neutropaenia 34 (24) 22 (22) 12 (26) 
Abbreviations: see List of abbreviations. 
Source: [17] 
 
Table 6.5. Summary of treatment-related SAEs in ≥3% of patients and AEs leading to treat-
ment discontinuation in at least 1 patient in the IIT 
 
Endpoint 
All patients 
(n=144) 
Aged ≤60 years 
(n=98) 
Aged >60 years 
(n=46) 
Treatment-related SAEs in ≥3% of patients overall, n (%) 
Lung infection 7 (5) 2 (2) 5 (11) 
Platelet count decreased 7 (5) 4 (4) 3 (7) 
Electrocardiogram QT 
prolonged  
6 (4) 4 (4) 2 (4) 
Diarrhoea 5 (3) 5 (5) 0  
Sepsis 5 (3) 3 (3) 2 (4) 
Cardiac disorder 4 (3) 4 (4) 0  
Colitis 4 (3) 4 (4) 0 
Nausea 4 (3) 2 (2) 2 (4) 
Vomiting 4 (3) 3 (3) 1 (2) 
Hepatobiliary disease 4 (3) 4 (4) 0  
Alanine aminotransferase 3 (2) 1 (1) 2 (4) 
AEs leading to treatment discontinuation in ≥2 patients overall, n (%) 
Graft vs. host disease 5 (3) 1 (1) 4 (9) 
Nausea 3 (2) 2 (2) 1 (2) 
Platelet count decreased 3 (2) 3 (3) 0  
Cardiac disorders 2 (1) 2 (2) 0  
Electrocardiogram QT 
prolonged 
2 (1) 0  2 (4) 
Hepatobiliary disease 2 (1) 2 (2)     0  
Abbreviations: see List of abbreviations. Source: [17] 
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7 PATIENT INVOLVEMENT 
 
After consultation with patient organisations, a Romanian patient with AML was identified. An 
open interview, based on the HTAi questionnaire template, was conducted with this patient. The 
experiences of the patient informed to some extend the outcomes taken into consideration for this 
joint assessment. The process for patient involvement in joint assessment REA is still under de-
velopment. 
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8 DISCUSSION 
 
Description and technical characteristics of midostaurin 
Midostaurin is a new orally administrated multi-target receptor tyrosine kinase inhibitor acting 
against FLT3, KIT, KDR, PKC, and PDGFR, leading to cell cycle arrest and apoptosis. It is a stau-
rosporine analog with potent activity against both ITD- and TKD-mutant as well as against wild-
type FLT3. [B0001] 
Health problem and current use of midostaurin 
AML is a rare condition, having an estimated incidence of 3.7 per 100,000 for the EU overall and 
is largely diagnosed in older patients. Approximately one-third of patients have FLT3 mutation-
positive disease. [A0023].  
Overall, the 5-year survival rate for AML is 20%–30%. Younger patients have better outcomes 
compared with older patients. Patients with FLT3 mutation have worse outcomes for OS, time to 
relapse and DFS compared with patients without FLT3.  [A0007]  
Midostaurin received marketing authorisation (EC decision) on 18th September 2017 for AML 
indication: in combination with standard daunorubicin and cytarabine induction and high-dose 
cytarabine consolidation chemotherapy, and for patients in complete response followed by 
midostaurin single-agent maintenance therapy for adults with newly diagnosed AML who are 
FLT3 mutation positive. The current use of midostaurin for AML treatment so far has been limited 
to clinical trials.   
The wide variation in standard chemotherapy across Europe could affect the applicability of re-
sults from the RATIFY study. The most-common therapies for AML comprise induction therapy 
with a combination of an anthracycline and continuous infusion of cytarabine followed by SCT, 
depending on risk group. Several anthracyclines at different dosages are recommended for use 
across European countries (e.g., idarubicin). Mitoxantrone can also be used instead of daunorubi-
cin. 
SCT is widely used in AML after induction therapy. Exclusion of SCT from the PICO in the scope 
of this assessment was justified by the RATIFY trial design, which permitted the use of SCT (al-
logeneic or autologous), although patients who underwent SCT were not to resume midostau-
rin/placebo therapy following SCT. Previous midostaurin treatment would not prevent eligible pa-
tients from SCT. Consequently, midostaurin and SCT treatments are not mutually exclusive and 
there is no available evidence to support such a comparison. 
GO was considered by the MAH as a relevant comparator because it has been used in France in 
a compassionate-use program since 2014 [1]. GO is currently under evaluation at EMA and did 
not have a license at the time of this assessment. Thus, GO was not considered in this European 
assessment as a relevant comparator because of its limited use in a selected population in only 
one member state.  
Clinical effectiveness 
Overall survival 
Midostaurin in combination with standard induction and consolidation chemotherapy improved OS 
in patients aged 18–60 years who are fit for chemotherapy (HR= 0.77, 95%CI: 0.63–0.95, 
p=0.0078). Thus, the risk of death was reduced by 23% during follow-up for midostaurin versus 
placebo. The proportion of patients alive was significantly higher at both the 1- and 5-year follow-
ups, demonstrating both short- and long-term positive effects of midostaurin on survival. Median 
OS was 25.6 months (95% CI: 18.6–42.9) for placebo and 74.7 months (95% CI: 31.5–not esti-
mable) for midostaurin-based therapy. The large difference in the OS medians is at least partly 
explained by the plateau effect and very few deaths occurred after 3 years of therapy, irrespective 
of the treatment group. Given this evident plateau effect, the absolute OS gain cannot be reliably 
determined. We, as authors, do not consider interpreting 49 months’ difference in OS medians as 
a reliable estimate for OS gain. Patients over 60 years of age have been studied in a single sin-
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gle-arm trial, but RCT-based evidence of the benefits of midostaurin in terms of OS among older 
patients is currently lacking. [D0001] 
Similar to the OS results, results for OS censored at SCT show a reduced risk of death for 
midostaurin over placebo (HR 0.75 [95% CI: 0.54–1.03]; p=0.0373). Approximately the same rela-
tive risk reduction in OS was demonstrated among patients undergoing SCT, patients not under-
going SCT and the overall study population. Consequently, SCT is unlikely to significantly con-
found the effect of midostaurin on OS, despite the high rates of patients receiving SCT (59.4% 
and 55.2% in the midostaurin and placebo groups, respectively). [D0001] 
There was no relevant heterogeneity in the effect on OS observed in subgroup analyses, except a 
difference in effect between males and females. This difference was not seen in subgroup anal-
yses of EFS or other secondary efficacy endpoints. The effect was also consistent for OS and 
EFS censored for SCT between males and females. In conclusion, the overall evidence does not 
allow us to conclude that the effect of midostaurin would be dramatically different between males 
and females. 
The MAH provided post-hoc subgroup analysis regarding NPM1 status. In terms of OS, relative 
risk reduction was approximately the same irrespective of NPM1 mutation status. These results 
were adjusted for the FLT3 mutation factor. It is unknown if the interaction of NPM1 and FLT3 
modifies the overall effect of midostaurin. These analyses were requested from the MAH during 
the assessment, but MAH could not provide them within the timeframe available. It remains there-
fore unclear whether the efficacy of midostaurin for, e.g., patients with NPM1 wild type and FLT3 
ITD with an allelic ratio ≥0.7 or patients with a NPM1 mutation and a FLT3 ITD mutation with allel-
ic ratio <0.7, would be the same.  
Indirect comparison of midostaurin in combination with standard induction and consolidation 
chemotherapy versus induction and consolidation chemotherapy with high-dose daunorubicin (90 
mg/m2) used during induction showed no difference between the treatments in terms of OS 
(daunorubicin 90 mg/m2 versus midostaurin/daunorubicin 60 mg/m2, HR=0.84, 95% CI: 0.54–
1.31). Consequently, there is no evidence that midostaurin treatment would be more beneficial 
than high-dose daunorubicin used during induction, or vice versa. Indirect comparisons were con-
ducted by authors. 
Serious limitations apply to these comparisons. First, the indirectness of evidence reduces the 
quality and credibility of the result overall. Second, full details of the FLT3-mutated subpopulation 
were not available for the study comparing 90 mg/m2 and 60 mg/m2 daunorubicin and thus, does 
not allow for the assessment of the similarity of the patient groups compared indirectly. Third, 
estimates of the effect of daunorubicin 90 mg/m2 were based on a post-hoc subgroup analysis, 
which might have impact on the result compared with an analysis conducted directly as a primary 
analysis for the full analysis set. Fourth, follow-up times for OS differed between the UK NCRI 
AML17 and RATIFY trials, being only 3 years in the former and approximately 6 years in the lat-
ter. This might have impact on the result if it is expected that the OS effect is time dependent. 
Fifth, there is limited similarity in the common reference arms (variation in regimens). The exact 
implications of these limitations are not fully clear because of the lack of information available. 
Consequently, drawing conclusions from this indirect comparison should be cautioned. 
Overall, evidence for the OS effect of midostaurin with standard chemotherapy versus standard 
chemotherapy is based on one appropriately designed and analysed RCT with a low risk of bias 
(see Appendix 1 and Tables A4 and A5). However, because of the design of the RATIFY trial, the 
disposition of patients and complex treatment overall, the effects of midostaurin during continua-
tion therapy are difficult to assess reliably, and only a small proportion of patients received 
midostaurin as a continuation therapy.  
The direct evidence is of high quality (see Appendix 1 and Tffigable A6). However, the indirect 
comparison of midostaurin and high-dose daunorubicin used during induction has several limita-
tions and the overall quality of indirect evidence is low. 
There are limitations in applicability related to evidence for OS. RCT evidence was only available 
for patients aged 18–60 years. The average age of patients in the RATIFY trial was 45.2 years, 
which is likely to be less than the average age of those typically treated in clinical practice. Also, 
the proportion of patients undergoing SCT in the RATIFY trial is likely to be higher than for those 
PTJA01 - Midostaurin with standard chemotherapy in FLT3 positive acute myeloid leukaemia 
 
Version 1.3, Novermber 2017 EUnetHTA Joint Action 3 WP4 67 
treated in clinical practice. This might be a reflection of the younger and healthier patient popula-
tion used in the trial. 
There was only very limited evidence for patients aged over 60 years and this evidence was 
based on a single-arm trial. Given these results, there is no reason to suspect that patients aged 
60 years or more would not benefit from midostaurin. Furthermore, the suitability of a patient for 
chemotherapy is more critical in terms of eligibility for treatment than is their actual age. However, 
there is a clear evidence gap concerning the effects of midostaurin in the older AML population. 
Significant proportion of the patients treated in clinical practice are older than 60 years of age, and 
the result of treatment can be generally expected to be worse than for younger patients. 
Another issue related to the applicability is the variation in the standard induction and consolida-
tion chemotherapy across countries and regions. Midostaurin has been studied in combination 
with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation 
chemotherapy, and with patients in DR followed by midostaurin monotherapy. There is no evi-
dence of midostaurin in combination with other induction and consolidation alternatives, except for 
those used in RATIFY. 
Other outcomes (EFS, CR, DFS, and CIR) 
EFS was improved by 27% in the midostaurin group compared with standard induction and con-
solidation chemotherapy (HR=0.73, 95% CI: 0.61–0.87, p=0.0001). EFS was a key secondary 
endpoint to be tested in a hierarchical manner if the OS endpoint was significant. EFS results 
censored at SCT were consistent with this result (HR=0.76, 95% CI: 0.63–0.92, p=0.0019). The 
effect of midostaurin on EFS was homogeneous across the subgroups, and the heterogeneity of 
effect between males and females that was seen in the OS result was not observed. In the IIT 
trial, median EFS was 13.8 months in patients aged ≤60 years. In patients over 60 years, the me-
dian EFS was 9.3 months. This indicates longer EFS for younger patients. 
Similarly, DFS from first CR was improved by 34% (HR= 0.66, 95% CI: 0.52–0.85, p=0.0006) and 
DFS censored at SCT improved by 28% (HR=0.72, 95% CI: 0.54–0.97, p=0.0150) in the 
midostaurin group compared with standard induction and consolidation chemotherapy. In addition, 
the results regarding DFS were in line with the OS results.  
Overall, the CR rate was higher in the midostaurin group (65% vs. 58%, p=0.027, one sided). In 
the IIT trial, a slightly higher proportion of patients in CR was observed in patients ≤60 years than 
in patients over 60 years (77% vs. 67%). 
Comparison of the CIR between the two treatment groups showed that midostaurin reduced the 
risk of relapse (HR 0.676 [95% CI: 0.52–0.89]; p=0.0023). Censoring for SCT reduced the differ-
ence between the treatment groups. 
Overall, key secondary outcomes support the conclusions based on the primary outcome (OS). 
Relative risk reductions in these other outcomes were in line with those observed in the OS anal-
yses.  
Similar restrictions to applicability apply to these outcomes as discussed in the OS section above. 
Health-related quality of life 
No evidence on HrQoL or disease-specific quality of life was available. This is considered to be a 
severe evidence gap from an HTA perspective and further research is needed to gain information 
on the effects of midostaurin on HrQoL and disease-specific quality of life. 
Safety 
The safety evaluation of midostaurin was mainly based on the RATIFY trial. All patients in the 
RATIFY trial experienced at least one AE of any grade regardless of its relation to the study drug. 
All except one patient in the midostaurin group experienced grade 3–4 AE(s). Approximately 50% 
of the patients in both groups experienced a SAE. 78% of patients in the midostaurin group and 
75% of patients in placebo group reported at least one grade 3-4 AE considered related to treat-
ment. Most events were reported during the induction and consolidation phases and events were 
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less frequently reported during the continuation phase. There were 36 deaths on-treatment (i.e., 
within 30 days of the last treatment; 15 and 21 in the midostaurin and placebo arms, respectively). 
[C0008] 
The most frequent grade 3–4 adverse events regardless of relationship to study drug were throm-
bocytopaenia, neutropaenia, anaemia and febrile neutropaenia. Grade 3-4 adverse events lead-
ing to discontinuation in more than one patient were dermatitis exfoliative, increased ALT, in-
creased AST, decreased neutrophil count and renal failure in the midostaurin group and de-
creased platelet count, febrile neutropaenia and decreased neutrophil count in the placebo group. 
Overall, 23 (6.7%) patients in the midostaurin group and 17 (5.1%) patients in the placebo group 
discontinued therapy because of grade 3–4 AEs. [C0008] 
Based on the safety results from the IIT trial, the treatment-related AEs and their severity were 
similar in patients aged ≤60 years and >60 years. The incidence of SAEs and discontinuation 
because of AEs were higher in older patients. Deaths occurred at a higher frequency in patients 
aged >60 years. [C0008].  
Overall, AEs were balanced between groups but rates of grade 3–4 AEs were high. However, this 
is typical considering the health condition. Grade 3–4 AEs emerging more frequently in the 
midostaurin group than in the placebo group were exfoliative dermatitis and device-related infec-
tions. Furthermore, QTc prolongation has been observed in patients receiving midostaurin. 
[C0008] 
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Ethical, organisational, social and legal aspects 
There were no potential concerns identified from an ethical, organisational, social or legal aspect 
that would be related to using midostaurin with standard induction and consolidation chemothera-
py. All patients receiving midostaurin must be tested for FLT3 mutation. This testing might not be 
implemented Europe wide, which could have some impact on the resource use in some countries. 
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9 CONCLUSION 
 
Midostaurin in combination with standard induction and consolidation chemotherapy is considered 
more effective than standard induction and consolidation chemotherapy alone in terms of im-
proved OS in patients aged 18–60 years who are suitable for intensive chemotherapy. The risk of 
death was reduced by 23% during the follow-up for midostaurin versus placebo. The proportion of 
patients alive was significantly higher at the 1- and 5-year follow-ups, demonstrating both short- 
and long-term positive effects of midostaurin on survival. More uncertainty is related to the benefi-
cial effects of midostaurin used in continuation therapy because of patient disposition in the trial 
leading to fewer patients receiving continuation therapy. Based on indirect comparison, there was 
insufficient evidence to determine whether midostaurin treatment was more beneficial than high-
dose daunorubicin (90 mg/m2) used during induction in terms of OS. Serious limitations apply to 
this comparison. Patients over 60-years old have not yet been studied in an RCT setting and the 
effect size of midostaurin on OS is unknown in this older population. However, age itself is not the 
limiting factor when using midostaurin, but rather patients’ suitability for chemotherapy.  
The safety profile of treatment with midostaurin is considered to be similar to that of standard in-
duction and consolidation chemotherapy. However, grade 3–4 exfoliative dermatitis and device-
related infections occurred more frequently in patients receiving midostaurin treatment. Further-
more, QTc prolongation has been observed in patients receiving midostaurin. Deaths during the 
study treatment period and 30-day follow-up period might occur more frequently in patients over 
60-years old compared with younger patients. 
Further research is needed (and is ongoing) to gain better understanding on the effects of 
midostaurin in the older population. Health-related quality of life and disease-specific quality of life 
should be studied, because this evidence is currently lacking. 
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APPENDIX 1: METHODS AND DESCRIPTION OF THE EVIDENCE USED 
 
DOCUMENTATION OF THE SEARCH STRATEGIES 
 
Search strategies used in MAH submission or related appendix [17]: 
Embase search string 
 Platform: Embase.com 
 URL: www.embase.com 
 Date searched: 07-Jun-2017 
 Hits: 781 
Table A1. Results for Embase search string. 
No. Query Results 
#1  'acute myeloid leukemia'/exp 88460 
#2  'myeloid leukemia'/exp AND 'acute disease'/exp 1514 
#3  acut*:ab,ti OR akut*:ab,ti OR agud*:ab,ti OR aigu*:ab,ti OR akuut*:ab,ti 1398975 
#4  ((myelo* OR mielo* OR müelo* OR mjelo* OR nonlympho* OR 'non lymphocytic' OR granulocyt* OR monoblast* OR monocyt* OR 'di gugliel-
mo' OR guglielmo* OR erythroid*) NEAR/3 (leukemi* OR leukaemi* OR leukämi* OR leukæmi* OR leukeemi* OR leuc* OR levkemi*)):ab,ti,de 
OR erythroleukemi*:ab,ti,de OR erythroleukaemi*:ab,ti,de 
156573 
#5  #3 AND #4 75735 
#6  aml:ab,ti,de OR anll:ab,ti,de 49187 
#7  #1 OR #2 OR #5 OR #6 117467 
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#8  'cd135 antigen'/exp OR 'flt3 ligand'/exp OR 'gene mutation'/exp OR 'internal tandem duplication'/exp OR 'fms like tyrosine kinase 3 receptor'OR 'flt3 
gene'/exp OR 'mutation'/exp 
963230 
#9  (antigen NEAR/3 cd135):ab,ti OR flt3*:ab,ti OR 'flt 3':ab,ti OR (fms* NEAR/3 ('tyrosine kinase 3' OR tk3 OR 'tk 3')):ab,ti OR (fe-
tal NEAR/3 liverNEAR/3 'tyrosine kinase 3'):ab,ti OR (stem NEAR/3 cell NEAR/3 'tyrosine kinase 1'):ab,ti OR stk1:ab,ti OR d835:ab,ti OR itd*:ab,ti 
OR tkd*:ab,ti OR kdm*:ab,ti OR 'kinase domain':ab,ti OR rtk*:ab,ti OR (receptor NEAR/3 tyrosine NEAR/3 kinase):ab,ti OR ((favoura-
ble* OR unfavourable*OR favorable* OR unfavorable OR good OR intermediate* OR poor* OR adverse OR high* OR increase*) NEAR/3 
(risk* OR karyotype*)):ab,ti OR fr:ab,ti OR 'ir 1':ab,ti OR 'ir i':ab,ti OR 'ir 2':ab,ti OR 'ir ii':ab,ti 
940838 
#10  #8 OR #9 1853023 
#11  (diagnos* NEAR/3 (new* OR recent*)):ab,ti OR '1st line':ab,ti OR ((first* OR initial) NEAR/3 
(course* OR cycle* OR line* OR treatment* OR therap* OR regimen* OR induction*)):ab,ti OR frontline:ab,ti OR 'front line':ab,ti OR upfront:ab,ti 
OR naïve*:ab,ti OR 'treatment naïve':ab,ti OR treatmentnaive:ab,ti OR untreated:ab,ti OR 'un treated':ab,ti OR 'previously untreated':ab,ti OR 'not previously 
treated':ab,ti OR 'no previous':ab,ti OR 'no prior':ab,ti 
683335 
#12  'antileukemic agent'/exp OR 'anthracycline'/exp OR 'anthracycline derivative'/exp OR 'induction chemotherapy'/exp OR 'unclassified drug'/exp OR 'health 
care quality'/exp OR 'gold standard'/exp OR 'placebo'/exp OR 'protein kinase inhibitor'/exp OR 'cytarabine'/exp OR 'daunorubicin'/exp OR 'cytarabine plus 
daunorubicin'/exp OR 'idarubicin'/exp OR 'mitoxantrone'/exp OR 'sorafenib'/exp OR 'midostaurin'/exp OR 'lestaurtinib'/exp OR 'quizartinib'/exp 
OR 'crenolanib'/exp OR 'gilteritinib'/exp OR 'gemtuzumab'/exp OR 'gemtuzumab ozogamicin'/exp OR 'tosedostat'/exp OR 'clofarabine'/exp 
5250514 
#13  anthracyclin*:ab,ti OR cytarabin*:ab,ti OR 'ara c':ab,ti OR arac:ab,ti OR cytosin*:ab,ti OR hdac:ab,ti OR daunorubicin*:ab,ti OR idarubicin*:ab,ti 
OR mitoxantron*:ab,ti OR sorafenib*:ab,ti OR midostaurin*:ab,ti OR lestaurtinib*:ab,ti OR quizartinib*:ab,ti OR crenolanib*:ab,ti OR gilteritinib*:ab,ti 
OR gemtuzumab*:ab,ti OR tosedostat*:ab,ti OR clofarabin*:ab,ti OR 'cpx 351':ab,ti OR cpx351:ab,ti OR ((standard OR conventional) NEAR/3 
(care OR therapy OR treatment* OR induction*)):ab,ti OR ((gold OR golden) NEAR/3 standard):ab,ti OR (soc NEAR/3 (standard OR care)):ab,ti 
OR placebo*:ab,ti OR ((induction OR intensive) NEAR/3 (chemotherapy OR therapy)):ab,ti OR ((fms OR flt3*) NEAR/4 inhibit*):ab,ti OR '5+2':ab,ti OR '5 + 
2':ab,ti OR '5 plus 2':ab,ti OR '2+5':ab,ti OR '2 + 5':ab,ti OR '2 plus 5':ab,ti OR '3+7':ab,ti OR '3 + 7':ab,ti OR '3 plus 7':ab,ti OR '7+3':ab,ti OR '7 + 3':ab,ti 
OR '7 plus 3':ab,ti OR '10+3':ab,ti OR '10 + 3':ab,ti OR '10 plus 3':ab,ti OR '3+10':ab,ti OR '3 + 10':ab,ti OR '3 plus 10':ab,ti 
1495763 
#14  #12 OR #13 6205098 
#15  'crossover procedure'/exp OR 'double blind procedure'/exp OR 'single blind procedure'/exp OR 'randomized controlled trial'/exp 507072 
#16  random*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR (cross NEAR/1 over*):ab,ti OR placebo*:ab,ti OR ((doubl* OR singl*) 
NEAR/1 blind):ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti 
1753268 
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#17  'randomized controlled trial':de 567401 
#18  #15 OR #16 OR #17 1906287 
#19  #7 AND #10 AND #11 AND #14 AND #18 673 
#20  'practice guideline'/exp OR guideline*:ti OR recommendation*:ti OR standards:ti 477033 
#21  'world health organization'/exp OR 'europe'/exp 1508338 
#22  europ*:ti,ca,cy OR britain:ti,ca,cy OR british:ti,ca,cy OR england:ti,ca,cy OR english:ti,ca,cy OR scotland:ti,ca,cy OR scottish:ti,ca,cy OR 'uk':ti,ca,cy 
OR wales:ti,ca,cy OR welsh:ti,ca,cy OR 'united kingdom':ti,ca,cy OR uk:ti,ca,cy OR austria*:ti,ca,cy OR albania*:ti,ca,cy OR balkan:ti,ca,cy 
OR baltic:ti,ca,cy OR bosnia*:ti,ca,cy OR bulgaria*:ti,ca,cy OR croat*:ti,ca,cy OR czech*:ti,ca,cy OR hungary:ti,ca,cy OR hungarian:ti,ca,cy 
OR magyar*:ti,ca,cy OR montenegro*:ti,ca,cy OR poland:ti,ca,cy OR polish:ti,ca,cy OR romania*:ti,ca,cy OR serbia*:ti,ca,cy OR slovak*:ti,ca,cy 
OR sloven*:ti,ca,cy OR belgium:ti,ca,cy OR belgian:ti,ca,cy OR benelux:ti,ca,cy OR france:ti,ca,cy OR french:ti,ca,cy OR german*:ti,ca,cy 
OR ireland:ti,ca,cy OR irish:ti,ca,cy OR liechtenstein:ti,ca,cy OR luxembourg*:ti,ca,cy OR monaco:ti,ca,cy OR netherlands:ti,ca,cy OR dutch:ti,ca,cy 
OR scandinavia*:ti,ca,cy OR nordic:ti,ca,cy OR norway:ti,ca,cy OR norwegian:ti,ca,cy OR sweden:ti,ca,cy OR swedish:ti,ca,cy OR denmark:ti,ca,cy 
OR danish:ti,ca,cy OR finland:ti,ca,cy OR finnish:ti,ca,cy OR greenland:ti,ca,cy OR iceland*:ti,ca,cy OR greece:ti,ca,cy OR greek:ti,ca,cy 
OR hellenic:ti,ca,cy OR spain:ti,ca,cy OR spanish:ti,ca,cy OR italy:ti,ca,cy OR italian:ti,ca,cy OR portugal:ti,ca,cy OR portuguese:ti,ca,cy 
OR switzerland:ti,ca,cy OR swiss:ti,ca,cy 
11054499 
#23  #21 OR #22 11713186 
#24  acut*:ti OR akut*:ti OR agud*:ti OR aigu*:ti OR akuut*:ti 573244 
#25  ((myelo* OR mielo* OR müelo* OR mjelo* OR nonlympho* OR 'non lymphocytic' OR granulocyt* OR monoblast* OR monocyt* OR 'di gugliel-
mo' OR guglielmo* OR erythroid*) NEAR/3 (leukemi* OR leukaemi* OR leukämi* OR leukæmi* OR leukeemi* OR leuc* OR levkemi*)):ti 
OR erythroleukemi*:ti OR erythroleukaemi*:ti 
58103 
#26  aml:ti OR anll:ti 8696 
#27  #24 AND #25 OR #26 37107 
#28  #20 AND #23 AND #27 AND [2006-2017]/py 158 
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#29  pediatric:ti OR paediatric:ti OR child*:ti NOT adult:ti 951827 
#30  #28 NOT #29 124 
#31  #19 OR #30 AND [embase]/lim 781 
 
Medline search string 
 Platform: Pubmed 
 URL: http://www.ncbi.nlm.nih.gov/pubmed/ 
 Date searched: 7-Jun-2017 
 Hits: 558 
Table A2. Results for Medline search string 
Search Query Items found 
#1 Search "Leukemia, Myeloid, Acute"[mh] 48387 
#2 Search ("Leukemia, Myeloid"[mh] AND "Acute Disease"[mh]) 7773 
#3 Search (acut*[tiab] OR akut*[tiab] OR agud*[tiab] OR aigu*[tiab] OR akuut*[tiab]) 1035579 
#4 Search (((myelo*[tiab] OR mielo*[tiab] OR müelo*[tiab] OR mjelo*[tiab] OR nonlympho*[tiab] OR “non lymphocytic”[tiab] OR granulocyt*[tiab] OR mono-
blast*[tiab] OR monocyt*[tiab] OR “Di Guglielmo”[tiab] OR Guglielmo*[tiab] OR erythroid*[tiab]) AND (leukemi*[tiab] OR leukaemi*[tiab] OR leukämi*[tiab] 
OR leukæmi*[tiab] OR leukeemi*[tiab] OR leuc*[tiab] OR levkemi*[tiab])) OR erythroleukemi*[tiab] OR erythroleukaemi*[tiab]) 
98720 
#5 Search (#3 AND #4) 51919 
#6 Search (aml[tiab] OR anll[tiab]) 27292 
#7 Search (#1 OR #2 OR #5 OR #6) 80527 
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#8 Search ("fms-Like Tyrosine Kinase 3"[mh] OR "FLT3 protein, human"[supplementary concept] OR "flt3 ligand protein"[supplementary concept] OR “muta-
tion”[mh]) 
669537 
#9 Search ((antigen[tiab] AND cd135[tiab]) OR flt3*[tiab] OR “flt 3”[tiab] OR (fms*[tiab] AND (“tyrosine kinase 3”[tiab] OR TK3[tiab] OR “TK 3”[tiab])) OR (fe-
tal[tiab] AND liver[tiab] AND “tyrosine kinase 3”[tiab]) OR (stem[tiab] AND cell[tiab] AND “tyrosine kinase 1”[tiab]) OR STK1[tiab] OR D835[tiab] OR 
ITD*[tiab] OR TKD*[tiab] OR KDM*[tiab] OR “kinase domain”[tiab] OR RTK*[tiab] OR (receptor[tiab] AND tyrosine[tiab] AND kinase[tiab]) OR ((favoura-
ble*[tiab] OR unfavourable*[tiab] OR favorable*[tiab] OR unfavorable[tiab] OR good[tiab] OR intermediate*[tiab] OR poor*[tiab] OR adverse[tiab] OR 
high*[tiab] OR increase*[tiab]) AND (risk*[tiab] OR karyotype*[tiab])) OR FR[tiab] OR “IR 1”[tiab] OR “IR I”[tiab] OR “IR 2”[tiab] OR “IR II”[tiab]) 
1303329 
#10 Search (#8 OR #9) 1930908 
#11 Search ((diagnos*[tiab] AND (newly[tiab] OR recent*[tiab])) OR “1st line”[tiab] OR ((first*[tiab] OR initial[tiab]) AND (course*[tiab] OR cycle*[tiab] OR 
line[tiab] OR treatment*[tiab] OR therap*[tiab] OR regimen*[tiab] OR induction*[tiab])) OR frontline[tiab] OR “front line”[tiab] OR upfront[tiab] OR na-
ïve*[tiab] OR “treatment naïve”[tiab] OR treatmentnaive[tiab] OR untreated[tiab] OR “un treated”[tiab] OR “previously untreated”[tiab] OR “not previously 
treated”[tiab] OR “no previous”[tiab] OR “no prior”[tiab]) 
1345605 
#12 Search (“Anthracyclines”[mh] OR "Induction Chemotherapy"[mh] OR "Quality of Health Care"[mh] OR “placebos”[mh] OR "Protein Kinase Inhibitors"[mh] 
OR "Protein Kinase Inhibitors" [pharmacological action] OR "Cytarabine"[mh] OR “mitoxantrone”[mh] OR “sorafenib”[supplementary concept] OR 
“midostaurin”[supplementary concept] OR “lestaurtinib”[supplementary concept] OR “quizartinib”[supplementary concept] OR “crenolanib”[supplementary 
concept] OR “gemtuzumab”[supplementary concept] OR “tosedostat”[supplementary concept] OR “clofarabine”[supplementary concept]) 
5942832 
#13 Search (anthracyclin*[tiab] OR cytarabin*[tiab] OR “ara C”[tiab] OR araC[tiab] OR cytosine[tiab] OR HDAC[tiab] OR daunorubicin*[tiab] OR idarubi-
cin*[tiab] OR mitoxantron*[tiab] OR sorafenib*[tiab] OR midostaurin*[tiab] OR lestaurtinib*[tiab] OR quizartinib*[tiab] OR crenolanib*[tiab] OR 
gilteritinib*[tiab] OR gemtuzumab*[tiab] OR tosedostat*[tiab] OR clofarabin*[tiab] OR ((standard[tiab] OR conventional[tiab]) AND (care[tiab] OR thera-
py[tiab] OR treatment*[tiab] OR induction*[tiab])) OR ((gold[tiab] OR golden[tiab]) AND standard[tiab]) OR (SOC[tiab] AND (standard[tiab] OR care[tiab])) 
OR placebo*[tiab] OR ((induction[tiab] OR intensive[tiab]) AND (chemotherapy[tiab] OR therapy[tiab])) OR ((fms[tiab] OR flt3*[tiab]) AND inhibit*[tiab]) OR 
“5+2”[tiab] OR “5 + 2”[tiab] OR “5 plus 2”[tiab] OR “2+5”[tiab] OR “2 + 5”[tiab] OR “2 plus 5”[tiab] OR “3+7”[tiab] OR “3 + 7”[tiab] “3 plus 7”[tiab] OR 
“7+3”[tiab] OR “7 + 3”[tiab] OR “7 plus 3”[tiab] OR “10+3”[tiab] OR “10 + 3”[tiab] OR “10 plus 3”[tiab] OR “3+10”[tiab] OR “3 + 10”[tiab] OR “3 plus 10”[tiab]) 
170618 
#14 Search (#12 OR #13) 6047106 
#15 Search (“randomized controlled trial”[pt] OR “controlled clinical trial”[pt] OR randomized[tiab] OR randomised[tiab] OR placebo*[tiab] OR randomly[tiab] 
OR trial[ti]) 
1001004 
#16 Search clinical trials as topic [mh:NoExp] 179646 
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#17 Search (#15 OR #16) 1125684 
#18 Search (#7 AND #10 AND #11 AND #14 AND #17) 490 
#19 Search (“practice guideline”[pt] OR "Practice Guidelines as Topic"[mh]) 119865 
#20 Search (guideline*[ti] OR recommendation*[ti] OR standards[ti]) 111646 
#21 Search (#19 OR #20) 189170 
#22 Search (“world health organization”[mh] OR “Europe”[mh]) 1271609 
#23 Search (Europ*[tiabtw] OR britain[tiabtw] OR British[tiabtw] OR England[tiabtw] OR English[tiabtw] OR Scotland[tiabtw] OR Scottish[t iabtw] or “UK”[tiabtw] 
OR wales[tiabtw] OR Welsh[tiabtw] OR “United Kingdom”[tiabtw] OR UK[tiabtw] OR Austria*[tiabtw] OR Albania*[tiabtw] OR Balkan[tiabtw] OR Bal-
tic[tiabtw] OR Bosnia*[tiabtw] OR Bulgaria*[tiabtw] OR Croat*[tiabtw] OR Czech*[tiabtw] OR Hungary[tiabtw] OR Hungarian[tiabtw] OR Magyar*[tiabtw] 
OR Montenegro*[tiabtw] OR Poland[tiabtw] OR Polish[tiabtw] OR Romania*[tiabtw] OR Serbia*[tiabtw] OR Slovak*[tiabtw] OR Sloven*[tiabtw] OR Bel-
gium[tiabtw] OR Belgian[tiabtw] OR Benelux[tiabtw] OR France[tiabtw] OR French[tiabtw] OR German[tiabtw] OR Germany[tiabtw] OR Ireland[tiabtw] OR 
Irish[tiabtw] OR Liechtenstein[tiabtw] OR Luxembourg*[tiabtw] OR Monaco[tiabtw] OR Netherlands[tiabtw] OR Dutch[tiabtw] OR Scandinavia*[tiabtw] OR 
Nordic[tiabtw] OR Norway[tiabtw] OR Norwegian[tiabtw] OR Sweden[tiabtw] OR Swedish[tiabtw] OR Denmark[tiabtw] OR Danish[tiabtw] OR Fin-
land[tiabtw] OR Finnish[tiabtw] OR Greenland[tiabtw] OR Iceland*[tiabtw] OR Greece[tiabtw] OR Greek[tiabtw] OR Hellenic[tiabtw] OR spain[tiabtw] OR 
Spanish[tiabtw] OR Italy[tiabtw] OR Italian[tiabtw] OR Portugal[tiabtw] OR Portuguese[tiabtw] OR Switzerland[tiabtw] or Swiss[tiabtw]) 
26237182 
#24 Search (#22 OR #23) 26264239 
#25 Search (acut*[ti] OR akut*[ti] OR agud*[ti] OR aigu*[ti] OR akuut*[ti]) 438679 
#26 Search (((myelo*[ti] OR mielo*[ti] OR müelo*[ti] OR mjelo*[ti] OR nonlympho*[ti] OR “non lymphocytic”[ti] OR granulocyt*[ti] OR monoblast*[ti] OR mono-
cyt*[ti] OR “Di Guglielmo”[ti] OR Guglielmo*[ti] OR erythroid*[ti]) AND (leukemi*[ti] OR leukaemi*[ti] OR Leukämi*[ti] OR leukæmi*[ti] OR leukeemi*[ti] OR 
leuc*[ti] OR levkemi*[ti])) OR erythroleukemi*[ti] OR erythroleukaemi*[ti]) 
46939 
#27 Search (#25 AND #26) 23446 
#28 Search (aml[ti] OR anll[ti]) 3574 
#29 Search (#27 OR #28) 26182 
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#30 Search (#21 AND #24 AND #29) 72 
#31 Search (paediatric[ti] OR pediatric[ti] OR child*[ti]) 767055 
#32 Search (#30 NOT #31) 68 
#33 Search (#18 OR #32) 558 
 
CENTRAL search string 
 Platform: Cochrane Library 
 URL: http://onlinelibrary.wiley.com/cochranelibrary/search/ 
 Date searched: 7-Jun-2017 
 Hits: 282 
Table A3. Results for CENTRAL search string 
ID Search Hits 
#1 MeSH descriptor: [Leukemia, Myeloid, Acute] explode all trees 987 
#2 MeSH descriptor: [Leukemia, Myeloid] explode all trees 1666 
#3 MeSH descriptor: [Acute Disease] explode all trees 9680 
#4 #2 and #3  288 
#5 (acut* or akut* or agud* or aigu* or akuut*):ti,ab,kw  90696 
#6 (((myelo* or mielo* or müelo* or mjelo* or nonlympho* or "non lymphocytic" or granulocyt* or monoblast* or monocyt* or "Di Guglielmo" or Guglielmo* or 
erythroid*) near/3 (leukemi* or leukaemi* or Leukämi* or leukæmi* or leukeemi* or leuc* or levkemi*)) or erythroleukemi* or erythroleukaemi*):ti,ab,kw  
4334 
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#7 #5 and #6  3269 
#8 (aml or anll):ti,ab,kw  2397 
#9 #1 or #4 or #7 or #8  4064 
#10 MeSH descriptor: [fms-Like Tyrosine Kinase 3] explode all trees 28 
#11 MeSH descriptor: [Mutation] explode all trees 2211 
#12 ((antigen near/3 cd135) or flt3* or "flt 3" or (fms* near/3 ("tyrosine kinase 3" or TK3 or "TK 3")) or (fetal near/3 liver near/3 "tyrosine kinase 3") or (stem near/3 
cell near/3 "tyrosine kinase 1") or STK1 or D835 or ITD* or TKD* or KDM* or "kinase domain" or RTK* or (receptor near/3 tyrosine near/3 kinase) or ((favour-
able* or unfavourable* or favorable* or unfavorable or good or intermediate* or poor* or adverse or high* or increase*) near/3 (risk* or karyotype*)) or FR or 
"IR 1" or "IR I" or "IR 2" or "IR II"):ti,ab,kw  
54832 
#13 #10 or #11 or #12  56781 
#14 ((diagnos* near/3 (new* or recent*)) or "1st line" or ((first* or initial) near/3 (course* or cycle* or line* or treatment* or therap* or regimen* or induction*)) or 
frontline or "front line" or upfront or naïve* or "treatment naïve" or treatmentnaive or untreated or "un treated" or "previously untreated" or "not previously 
treated" or "no previous" or "no prior"):ti,ab,kw  
54944 
#15 MeSH descriptor: [Anthracyclines] explode all trees 4361 
#16 MeSH descriptor: [Induction Chemotherapy] explode all trees 240 
#17 MeSH descriptor: [Quality of Health Care] explode all trees 424283 
#18 MeSH descriptor: [Placebos] explode all trees 23271 
#19 MeSH descriptor: [Protein Kinase Inhibitors] explode all trees 687 
#20 MeSH descriptor: [Cytarabine] explode all trees 916 
#21 MeSH descriptor: [Mitoxantrone] explode all trees 400 
#22 (anthracyclin* or cytarabin* or "ara C" or araC or cytosin* or HDAC or daunorubicin* or idarubicin* or mitoxantron* or sorafenib* or midostaurin* or les-
taurtinib* or quizartinib* or crenolanib* or gilteritinib* or gemtuzumab* or tosedostat* or clofarabin* or "CPX 351" or CPX351 or ((standard or conventional) 
283010 
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near/3 (care or therapy or treatment* or induction*)) or ((gold or golden) near/3 standard) or (SOC near/3 (standard or care)) or placebo* or ((induction or 
intensive) near/3 (chemotherapy or therapy)) or ((fms or flt3*) near/4 inhibit*) or "5+2" or "5 + 2" or "5 plus 2" or "2+5" or "2 + 5" or "2 plus 5" or "3+7" or "3 + 
7" or "3 plus 7" or "7+3" or "7 + 3" or "7 plus 3" or "10+3" or "10 + 3" or "10 plus 3" or "3+10" or "3 + 10" or "3 plus 10"):ti,ab,kw  
#23 #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22  567752 
#24 #9 and #13 and #14 and #23  291 
#25 MeSH descriptor: [Practice Guideline] explode all trees 16 
#26 MeSH descriptor: [Practice Guidelines as Topic] explode all trees 2071 
#27 (guideline* or recommendation* or standards):ti 4160 
#28 #25 or #26 or #27  5501 
#29 MeSH descriptor: [World Health Organization] explode all trees 301 
#30 MeSH descriptor: [Europe] explode all trees 26835 
#31 (Europ* or britain or British or England or English or Scotland or Scottish or "UK" or wales or Welsh or "United Kingdom" or UK or Austria* or Albania* or 
Balkan or Baltic or Bosnia* or Bulgaria* or Croat* or Czech* or Hungary or Hungarian or Magyar* or Montenegro* or Poland or Polish or Romania* or Serbia* 
or Slovak* or Sloven* or Belgium or Belgian or Benelux or France or French or German* or Ireland or Irish or Liechtenstein or Luxembourg* or Monaco or 
Netherlands or Dutch or Scandinavia* or Nordic or Norway or Norwegian or Sweden or Swedish or Denmark or Danish or Finland or Finnish or Greenland or 
Iceland* or Greece or Greek or Hellenic or spain or Spanish or Italy or Italian or Portugal or Portuguese or Switzerland or Swiss):ti,ab,kw  
117957 
#32 #29 or #30 or #31  119088 
#33 (acut* or akut* or agud* or aigu* or akuut*):ti 47031 
#34 (((myelo* or mielo* or müelo* or mjelo* or nonlympho* or "non lymphocytic" or granulocyt* or monoblast* or monocyt* or "Di Guglielmo" or Guglielmo* or 
erythroid*) near/3 (leukemi* or leukaemi* or Leukämi* or leukæmi* or leukeemi* or leuc* or levkemi*)) or erythroleukemi* or erythroleukaemi*):ti 
2812 
#35 #33 and #34  1958 
#36 (aml or anll):ti 1117 
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#37 #35 or #36  2557 
#38 #28 and #32 and #37  0 
#39 #24 or #38  291 
#40 #39 in Trials 282 
 
Details of hand searches 
 
Table A4. Conferences included in the literature search 
Research meeting Keywords Hits Relevant 
58th ASH Annual Meeting December 2016 
acute myeloid leukemia, acute myelogenous leukemia, acute 
myeloblastic leukaemia, FLT3 
106 1 
21st EHA Congress 9-12 June 2016, 
Copenhagen, Denmark 
acute myeloid leukemia 
108 4 
22nd EHA Congress 22-25 June 2017, Madrid, 
Spain 
acute myeloid leukemia 
132 1 
 
Table A5. Registries included in the literature search (26th June 2017) 
Database 
Search strategy Hits Relevant 
US NIH registry & results database 
Advanced search  
Search terms: FLT3 /  
Condition: acute myeloid leukaemia OR FLT3 
116 3 
WHO ICTRP registry 
Advanced search 
Search terms: FLT3* in Title AND acute myeloid leuk* OR 
FLT3* in Condition   
Recruitment status: ALL 
56 1 
EU Clinical Trial Registry 
Basic search 
Search terms: acute myeloid leuk* AND FLT3* 
41 3 
PTJA01 - Midostaurin with standard chemotherapy in FLT3 positive acute myeloid leukaemia 
 
Version 1.3, Novermber 2017 EUnetHTA Joint Action 3 WP4 86 
 
Additional results of searches 
 
Table A6. HTA-websites literature search 
Database 
Keywords Hits Relevant 
NICE FLT3, acute myeloid leukemia 22 3 
HAS FLT3, acute myeloid leukemia 18 1 
SBU FLT3, acute myeloid leukemia 0 0 
G-BA FLT3, acute myeloid leukemia 71 0 
Abbreviations: see list of abbreviations. 
 
Table A7. HTA websites relevant hits 
Health Technology 
Assessment (HTA) 
site 
Source Name of the document 
NICE https://www.nice.org.uk/guidance/gid-ta10124/documents/scope-consultation-comments-and-
responses 
Midostaurin for untreated acute myeloid leukaemia 
[ID894]. 
https://www.nice.org.uk/guidance/indevelopment/gid-ta10142 Gemtuzumab ozogamicin for untreated de novo acute 
myeloid leukaemia [ID982]. 
HAS https://www.has-sante.fr/portail/jcms/c_401011/en/zavedos?xtmc=&xtcr=2 Zavedos. 
Abbreviations: see List of abbreviations. 
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DESCRIPTION OF THE EVIDENCE USED  
 
Guidelines for diagnosis and management  
 
Table A8: Overview of guidelines 
Name of society/organisation issuing 
guidelines 
Date of issue 
or last update 
Countries to 
which 
guideline 
applies 
Summary of recommendations 
(Level of evidence/grade of recommendation for the indication under 
assessment) 
Level of evidence 
(A, B, C)/ class of 
recommendation 
(I, IIa, IIb, III) 
[50] 2006 UK Diagnosis 
Bone marrow aspirate, bone marrow trephine biopsy; immunophenotyping; 
cytochemistry; cytogenetics 
Management 
Induction 
Intensive: cytarabine + daunorubicin 
Nonintensive: LDAC 
BSC: transfusion support + hydroxycarbamide 
Consolidation 
Chemotherapy + SCT 
Salvage therapy 
Cytarabine (low, intermediate, or high doses) ± other drugs (e.g., fludarabine, 
daunorubicin + etoposide) 
 
A/Ib 
A/Ib 
Unclear for SCT 
B/IIb 
[26] 2013 Europe Diagnosis 
Morphology, cytochemistry, immunophenotyping, cytogenetics and molecular 
genetics work up on peripheral blood and bone marrow specimens 
 
PTJA01 - Midostaurin with standard chemotherapy in FLT3 positive acute myeloid leukaemia 
 
Version 1.3, Novermber 2017 EUnetHTA Joint Action 3 WP4 88 
Name of society/organisation issuing 
guidelines 
Date of issue 
or last update 
Countries to 
which 
guideline 
applies 
Summary of recommendations 
(Level of evidence/grade of recommendation for the indication under 
assessment) 
Level of evidence 
(A, B, C)/ class of 
recommendation 
(I, IIa, IIb, III) 
Management 
Induction 
Cytarabine + daunorubicin (± hematopoietic growth factors) 
BSC: LDAC or decitabine or azacitidine 
Consolidation 
IDAC or HDAC in good-risk patients 
SCT in patients with intermediate- to poor-risk AML provided age and PS 
make the patient eligible 
Salvage 
Re-induction 
SCT 
BSC 
A/I 
A/I 
B/II 
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Name of society/organisation issuing 
guidelines 
Date of issue 
or last update 
Countries to 
which 
guideline 
applies 
Summary of recommendations 
(Level of evidence/grade of recommendation for the indication under 
assessment) 
Level of evidence 
(A, B, C)/ class of 
recommendation 
(I, IIa, IIb, III) 
[33] 2017 Europe Diagnosis 
Complete blood count and differential count; bone marrow aspirate, bone 
marrow trephine biopsy; immunophenotyping 
Genetic analysis 
Management of patients eligible for intensive CT 
Induction 
Anthracycline plus cytarabine: 
3 days of an anthracycline: daunorubicin ≥60 mg/m2, idarubicin 12 mg/m2, or 
mitoxantrone 12 mg/m2 plus 
7 days of cytarabine, 100–200 mg/m2 continuous infusion 
Consolidation 
18–65 years favourable-risk genetics: IDAC 
18–65 years intermediate-risk genetics: alloSCT; IDAC or HDCT plus autolo-
gous SCT 
18–65 years adverse-risk genetics: alloSCT 
>60/65 years favourable-risk genetics: IDAC 
>60/65 years intermediate/adverse-risk genetics: consider alloSCT or investi-
gational therapy 
Management of patients ineligible for intensive CT 
Azacitadine, decitabine, LDAC, BSC 
Salvage regimens 
IDAC (with or without anthracycline) 
FLAG-IDA 
MEC 
AlloSCT 
 
 
 
 
 
 
Not stated in 
publication 
[49] 2009 Italy Induction 
Standard induction therapy: cytarabine + daunorubicin, idarubicin or mitoxan-
trone 
But not recommended for: >80 years, severe comorbidity or poor PS who 
should receive cytoreductive therapy (attenuated doses and/or oral admin-
A 
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Name of society/organisation issuing 
guidelines 
Date of issue 
or last update 
Countries to 
which 
guideline 
applies 
Summary of recommendations 
(Level of evidence/grade of recommendation for the indication under 
assessment) 
Level of evidence 
(A, B, C)/ class of 
recommendation 
(I, IIa, IIb, III) 
istration) and/or experimental therapies with significantly lower non-
haematologic toxicities 
Patients >65 years and not eligible for SCT should receive experimental ther-
apies with limited non-haematologic toxicities, cytoreductive agents and BSC 
Consolidation 
Patients in first complete response should receive a consolidation treatment 
as soon as the haematologic recovery from induction therapy has occurred 
Adults <60 years should receive post-remission consolidation chemotherapy 
based on HDAC; the number of cycles should not exceed 3–4 
B 
B 
D 
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Name of society/organisation issuing 
guidelines 
Date of issue 
or last update 
Countries to 
which 
guideline 
applies 
Summary of recommendations 
(Level of evidence/grade of recommendation for the indication under 
assessment) 
Level of evidence 
(A, B, C)/ class of 
recommendation 
(I, IIa, IIb, III) 
Potential candidates for allogeneic SCT should receive a shorter intensive 
consolidation including IDAC/HDAC in order to spare undue toxicity 
Potential candidates for autologous SCT should receive at least one inten-
sive consolidation cycle including IDAC/HDAC before collecting stem cells 
and performing autograft  
Elderly patients (>60 years) should not receive HDAC-based consolidation 
therapy and no more than two consolidation cycles 
 
AlloSCT consolidation 
From fully matched sibling donor is recommended in first CR for: 
1) adults with high-risk cytogenetics provided that they are aged <55 years 
and do not carry severe comorbidities  
2) adult patients with intermediate-risk cytogenetics with the exception of 
NPM1 mutation and FLT3-ITD-negative cases, provided that they are aged 
under 40 years and do not carry severe comorbidities  
3) patients who achieved a first CR only after having received a second 
course of induction therapy, irrespectively of their cytogenetic risk, provided 
that they are aged under 55 years and do not carry severe comorbidities 
AlloSCT from unrelated donor (if no fully matched sibling donor available) is 
 
 
 
 
 
 
 
 
 
D 
PTJA01 - Midostaurin with standard chemotherapy in FLT3 positive acute myeloid leukaemia 
 
Version 1.3, Novermber 2017 EUnetHTA Joint Action 3 WP4 92 
Name of society/organisation issuing 
guidelines 
Date of issue 
or last update 
Countries to 
which 
guideline 
applies 
Summary of recommendations 
(Level of evidence/grade of recommendation for the indication under 
assessment) 
Level of evidence 
(A, B, C)/ class of 
recommendation 
(I, IIa, IIb, III) 
recommended for all adult patients in first complete response aged under 30 
years with high-risk cytogenetics, or who achieved first CR only after a second 
course of induction therapy 
Autologous SCT consolidation 
Consolidation autologous SCT is recommended for patients eligible for high-
dose chemotherapy who are not candidates for allogeneic SCT from a fully 
HLA-matched donor 
D 
[24]  2016 Norway Diagnosis 
Morphological examination of bone marrow smear after MGG staining  
Cytochemical staining of bone marrow smears  
In patients with induction treatment with a view to complete remission, ghd is 
required as well:  
Cytogenetic examination of bone marrow cells  
Molecular genetic examination of bone marrow cells  
Flow cytomy with immune phenotyping of bone marrow cells 
Management induction phase 
<65 years 
daunorubicin 90 mg/m2 daily for 3 days or idarubicin 12 mg/m2 daily for 3 
days, both in combination with cytarabine 200 mg/m2 body surface/day as a 
 
A 
A 
A 
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Name of society/organisation issuing 
guidelines 
Date of issue 
or last update 
Countries to 
which 
guideline 
applies 
Summary of recommendations 
(Level of evidence/grade of recommendation for the indication under 
assessment) 
Level of evidence 
(A, B, C)/ class of 
recommendation 
(I, IIa, IIb, III) 
continuous infusion for 7 days. 
>65 years 
after individual assessment daunorubicin 60 mg/m2/day for 3 days and cytara-
bine 200 mg/m2/day for 7 days 
Consolidation  
Up to 60 years: HDAC (3 g/m2 days 1,3 and 5) or treatment according 
HOVONSAKK protocol cytarabine + daunorubicin 
>65 years  
STC should be considered Patients up to 70 years of age who have a suita-
ble family provider and yet not transplanted in the first remedy may be candi-
dates for allogeneic stem cell transplant at the beginning of their stay and 
should therefore be closely monitored while in first remission 
Consolidation: Mitoxantrone, amsacrine, etoposide, or Daunorubicin + cytar-
abine, azacitidine, or cytarabine 
>65 years ineligible for intensive chemotherapy – palliative care 
A/B 
B 
C 
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Name of society/organisation issuing 
guidelines 
Date of issue 
or last update 
Countries to 
which 
guideline 
applies 
Summary of recommendations 
(Level of evidence/grade of recommendation for the indication under 
assessment) 
Level of evidence 
(A, B, C)/ class of 
recommendation 
(I, IIa, IIb, III) 
[23] 2017 USA <60 years  
Induction: clinical trial, cytarabine plus idarubicin or daunorubicin ± cladribine; 
or HDAC + idarubicin or daunorubicin; cytarabine + daunorubicin + midostau-
rin; or fludarabine + HDAC + idarubicin + G-CSF 
CR: consolidation, i.e., HDAC, trial, or SCT 
Induction failure: trial, matched SCT or HDAC ± anthracycline or BSC 
Consolidation:  
Favourable-risk genetics: trial or HDAC 
Intermediate-risk genetics: trial, alloSCT or HDAC 
Poor-risk genetics: trial, alloSCT 
≥60 years and eligible for intensive therapy 
Induction:  
Without unfavourable genetic risk: trial, cytarabine + idarubicin or daunorubi-
cin or mitoxantrone 
With unfavourable genetic risk: trial, or 5-azacytidine or decitabine or cytara-
bine with idarubicin/daunorubicin/mitoxantrone, or clofarabine 
Consolidation: 
CR: trial, cytarabine ± anthracycline or IDAC or 5-azacytidine or decitabine 
Induction failure: trial, alloSCT, BSC 
 
 
 
 
 
 
 
 
Most recommen-
dations are class 
2A  
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Name of society/organisation issuing 
guidelines 
Date of issue 
or last update 
Countries to 
which 
guideline 
applies 
Summary of recommendations 
(Level of evidence/grade of recommendation for the indication under 
assessment) 
Level of evidence 
(A, B, C)/ class of 
recommendation 
(I, IIa, IIb, III) 
Nationellt vårdprogram Akut myeloisk 
leukemi 2016 
http://www.sfhem.se/nyheter/nationellt-
vardprogram-aml. 
 
http://www.sfhem.se/riktlinjer 
 
2016 Sweden Induction & consolidation therapy 
Cyclus 1 & 2 (DA3+5) 
  Day 
Daunorubicin  60 mg/m2 × 1  iv infusion 8 h  1, 2, 3  
Cytarabin  1 g/m2 × 2  iv infusion 2 h  1, 2, 3, 4, 5  
 
Cyclus 3 (DA2+5) 
 
   
  Daunorubicin       60 mg/m2 × 1     iv infusion 8 h     1, 2 
  Cytarabin              1 g/m2 × 2          iv infusion 2 h     1, 2, 3, 4, 5 
 
 Cyclus 5 (DA  
 
   Cytarabin             1 g/m2 × 2          iv infusion 2 h      1, 2, 3, 4, 5 
Patient not responding for induction therapy 
Azacitidine           75 mg/m2             s.c.                        1-7 
    
Abbreviations: see List of abbreviations. 
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Evidence tables of individual studies included for clinical effectiveness and safety 
 
 
Table A9: Characteristics of randomised controlled studies 
Trial number  
(acronym)  
CPKC412A2301, CALGB 10603 (RATIFY)  
Location Multicentre international study; 225 sites in 17 countries (including Australia, Canada, Germany, Italy, the Netherlands, Spain, 
the US). A total of 3277 patients were screened in 17 countries but only 13 countries randomised patients: Australia (2), Aus-
tria (12), Belgium (8), Canada (13), Czech Republic (11), France (5), Germany (305) Hungary (2), Italy (105), The Netherlands 
(5), Slovakia (4), Spain (22), US (223). 
Trial design  A phase III, 1:1 randomised, double-blind, placebo-controlled trial  
Patients stratified by FLT3 mutation subtype (TKD vs. ITD high allelic mutation fraction [≥0.7] vs. ITD low mutation fraction 
[<0.7]) 
Eligibility criteria for participants Inclusion criteria 
 
 Unequivocal diagnosis of AML (>20% blasts in the bone marrow based on the WHO classification, excluding M3 
[acute promyelocytic leukaemia]) 
 Documented FLT3 mutation (ITD or TKD), determined by analysis in a protocol-designated FLT3 screening laboratory 
 Age ≥18 and <60 years 
 No prior chemotherapy for leukaemia or myelodysplasia (exceptions: emergency leukapheresis, emergency treatment 
for hyperleukocytosis with hydroxyurea for ≤5 days, single dose of cranial radiation therapy for central nervous system 
leukostasis, growth factor/cytokine support) 
 
Exclusion criteria 
 
 AML blasts in the CSF (in patients with symptoms suggestive of CNS leukaemia) 
 Therapy-related AML after prior radiation therapy or chemotherapy for another cancer or disorder 
 Symptomatic congestive heart failure 
 Total bilirubin ≥2.5 × ULN 
 History of antecedent MDS in patients who had prior cytotoxic therapy (e.g., azacitidine or decitabine) 
 Pregnant or nursing patients 
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Trial number  
(acronym)  
CPKC412A2301, CALGB 10603 (RATIFY)  
Settings and locations where the data were 
collected 
Secondary care (hospital) setting 
Trial drugs (the interventions for each group 
with sufficient details to allow replication, 
including how and when they were adminis-
tered) 
Permitted and disallowed concomitant medi-
cation 
Interventional arm, n=360 
Comparator arm, n=357 
Induction phase (1–2 cycles): IV cytarabine 200 mg/m2/day (days 1–7) + IV daunorubicin 60 mg/m2/day (days 1–3) + oral 
Rydapt® 50 mg BID (days 8–21) 
Consolidation phase (4 cycles): IV cytarabine 3 g/m2 every 12 hours (days 1–7) + oral Rydapt® 50 mg BID (days 8–21) 
Maintenance phase (up to 12 cycles): oral Rydapt® 50 mg BID (days 1–28) 
Concomitant therapy: 
 Patients were to receive dexamethasone 0.1% or corticosteroid ophthalmic solution starting 6–12 hours prior to the 
initiation of the high-dose cytarabine infusion and therapy was to be continued for at least 24 hours after the last cy-
tarabine dose 
 Patients were to receive full supportive care, including blood transfusions and products 
 Myeloid growth factors were not to be used routinely or prophylactically, but were permitted as indicated by the Ameri-
can Society of Clinical Oncology guidelines for neutropenic patients; use of growth factors was to be documented 
 
Use of the following concomitant drugs was to be recorded:  
Antibiotic/antiviral/antifungal agents, proton pump inhibitors or H2-receptor antagonists, nonsteroidal anti-inflammatory drugs, 
opioids, antiemetic agents, antihistamines, corticosteroids, growth factors, diuretics, antihypertensives, and other CYP3A4 
inhibitors and CYP3A4 inducers 
Disallowed concomitant drugs:  
 Hormones, except for steroids given for adrenal failure or to treat and/or prevent hypersensitivity reactions or transfu-
sion reactions and hormones administered for non-disease-related conditions 
 Other chemotherapeutic agents 
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Trial number  
(acronym)  
CPKC412A2301, CALGB 10603 (RATIFY)  
Patients who underwent SCT were not to resume Rydapt®/placebo therapy 
Primary outcomes (including scoring meth-
ods and timings of assessments)  
OS  
Secondary/tertiary outcomes (including scor-
ing methods and timings of assessments) 
 Key secondary objective: EFS  
 Other secondary endpoints:  
 CR  
 DFS 
 CIR 
 OS, EFS and DFS censored at time of SCT 
 Safety (frequency and severity of adverse events and laboratory abnormalities) 
Pre-planned subgroups Subgroups defined based on baseline characteristics 
 FLT3 mutation status 1 (stratification factor): TKD mutation-positive patients, ITD mutation-positive patients with 
allelic ratio <0.7, ITD mutation-positive patients with allelic ratio ≥0.7 
 FLT3 mutation status 2: TKD mutation-positive patients, ITD mutation-positive patients with allelic ratio <0.50, ITD 
mutation-positive patients with allelic ratio ≥0.50 
 FLT3 mutation subtype: TKD mutation-positive patients vs. ITD mutation-positive patients 
 Gender 
 Region: North America vs. non-North America 
 Prior MDS: Yes vs. No 
 Cytogenetic profile: AML with t(8;21) (q22; q22), AML with inv(16) (p13; q22) or t(16;16) (p13; q22), AML with 11q23 
(MLL) abnormalities, other 
 WBC count at baseline: <50 × 109/L vs. ≥50 × 109/L 
 Race: Asian, Black or African American, White, Other (American Indian or Alaskan Native, Native Hawaiian or other 
Pacific Islander, other, unknown, more than one race) 
 ECOG Performance Status: 0–1 vs. ≥2 
Hypothesis objective To evaluate the effect on OS of adding Rydapt® to standard chemotherapy (induction therapy –daunorubicin/cytarabine – and 
consolidation therapy – high-dose cytarabine), followed by Rydapt® monotherapy in patients with newly diagnosed FLT3 
mutation-positive AML 
Statistical analysis • Stratified log-rank tests adjusting for the FLT3 mutation strata were used to test the null hypothesis and calculate the one-
sided p-value 
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Trial number  
(acronym)  
CPKC412A2301, CALGB 10603 (RATIFY)  
• Stratified Cox regression models adjusting for FLT3 mutation were used to estimate HRs and Wald 95% CIs 
• Kaplan–Meier plots were used to depict time to event endpoints 
• Median survival time and 95% CIs were calculated using the method of Brookmeyer and Crowley (1982)97 
• Kaplan–Meier estimates with 95% CIs at specific time points were summarized using Greenwood’s formula for the stand-
ard error of the Kaplan–Meier estimate 
• CR rates were compared using Cochran-Mantel-Haenszel test stratified for FLT3 mutation strata at one-sided 2.5% level 
Sample size, power calculation • Initial protocol: 514 patients and 374 events were estimated to be necessary to attain a 90% power with an accrual period 
of 1.7 years (i.e., 20.5 months) and a follow-up period of 2.0 years (i.e., 24 months) after accrual termination assuming an 
HR of 0.71. (Median OS: placebo, 15 months; midostaurin, 21 months) 
• The protocol was amended in December 2010, on the basis of a review of the blinded data, which indicated a higher than 
expected rate of randomisation of FLT3-TKD patients (increased from 14% to 26%) and a higher percentage of patients 
undergoing SCT (increased from 15% to 25%). The sample size was thus increased to accrue a total of 714 patients, with 
a 2.9-year accrual period and 1.6-year follow-up period from the time the last patient was randomised. A total of 509 OS 
events were expected by May 2013, to attain a power of 84% for the ITT analysis on OS to detect a HR of 0.78 with a 
one-sided test at an overall one-sided alpha level of 2.5% 
Data management, patient withdrawals • Patients who discontinued study treatment remained in the study and were followed up for response status (if in CR when 
discontinuing), long-term survival and SCT status 
• Patients who were prematurely withdrawn from the study were not replaced by newly enrolled patients  
• Patients with an up-to-date vital status and who were alive on or after 01 April 2015 were censored for the OS analysis. 
Patients indicated as being dead after 1st April 2015 were censored on 1st April 2015 in the primary analysis 
 
Abbreviations: see List of abbreviations. 
Sources: [17]  
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Table A10: Characteristics of other relevant studies  
Primary reference 
source 
Study type  Number of pa-
tients 
Intervention(s) Comparator 
(Number of pa-
tients) 
If applicable  
Patient population Endpoints Duplicate publica-
tions from the same 
study 
Investigator-initiated 
trial (AMLSG 16-
10.CPKC412ADE02T); 
primary reference:  
[17] 
Phase II single-
arm, multicentre, 
investigator-
initiated study 
n=145 Midostaurin plus 
daunorubicin plus 
cytarabine 
NA  Patients aged 
18–70 years 
with newly 
diagnosed 
FLT3-ITD-
positive AML  
 WHO 
Performance 
Status of ≤2  
 Considered 
eligible for 
intensive 
chemotherapy 
and had 
received no 
prior 
chemotherapy 
for leukaemia 
except 
hydroxyurea to 
control 
hyperleukocytos
is (received for 
≤7 days) 
EFS  
Other: 
 CR 
 RFS 
 OS 
[19, 20] 
UK NCRI AML17 trial Phase III random-
ised controlled trial 
Daunorubicin 90 
mg/m2 n=604 (100 
Daunorubicin 
90mg/m2 (d1,3,5) 
in course 1, then 
Daunorubicin 
60mg/m2 (d1,3,5) in 
course 1, then 
Patients with any 
form of AML 
(excluding acute 
OS (3-year fol-
low-up) 
[10] 
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primary reference:  
[10, 11] 
with FLT3 ITD)  
Daunorubicin 60 
mg/m2 n=602 (100 
with FLT3 ITD) 
50mg/m2 (d1,3,5) 
in course 2, with 
Ara-C 100mg/m2 
12-hourly d1-10 
(course 1) and d1-
8 (course 2). 
50mg/m2 (d1,3,5) in 
course 2, with Ara-
C 100mg/m2 12-
hourly d1-10 
(course 1) and d1-8 
(course 2). 
promyelocytic 
leukaemia) and 
high-risk 
myelodysplastic 
syndrome (MDS), 
predominantly aged 
18-60 years. 
Subgroup of 
patients with FLT3-
ITD mutation was 
used in the 
analysis. 
Abbreviations: see List of abbreviations. 
 
List of ongoing and planned studies 
 
Table A11: List of ongoing and planned studies  
Trial (NCT number) Status Therapy (drugs) Phase 
of study 
 
Patients Expected date of reporting 
Primary completion Study completion 
NCT02668653 Recruiting Cytarabine, Daunorubicin, 
Idarubicin, 
Quizartinib 
3 Newly Diagnosed FLT3-
ITD (+) AML 
January 2020 — 
NCT00651261 
 
Active, not 
recruiting 
Cytarabine, 
Daunorubicin, 
Midostaurin, 
dexamethasone acetate 
3 Newly Diagnosed AML July 2016  
 
— 
 
NCT01371981 Recruiting Asparaginase, Bortezomib, 
Cytarabine, 
Daunorubicin, Etoposide, 
Mitoxantrone, Sorafenib Tosylate 
3 Newly Diagnosed AML June 2017 — 
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ACTRN12611001112954 Not 
recruiting 
Cytarabine, Idarubicin, Sorafenib 2 Untreated AML patients 
with FLT3-ITD mutation 
— — 
EUdraCT no. 2008-004968-40 Completed Sorafenib with standard primary 
therapy 
2 Newly Diagnosed AML — September 2014 
EUdraCT no. 2006-006852-37/ 
NCT00651261 (RATIFY) 
Not 
recruiting, 
ongoing 
Midostaurin, cytarabine, 
daunorubicin, SCT 
3 Newly Diagnosed FLT3-
ITD AML 
June 2016 — 
EUdraCT no. 2005-005966-35 Completed Sorafenib with standard primary 
therapy 
2 Newly Diagnosed AML — July 2009 
Abbreviations: see List of abbreviations. 
Source: [17] 
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Risk of bias tables 
 
Table A12: Risk of bias – study level (RCTs)  
Trial 
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-
c
a
u
s
e
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o
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a
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ty
) 
RATIFY (CALGB 
10603/ 
CPKC412A2301) 
Low Low Low Low Low Low Low 
UK NCRI AML17 
trial  
Unclear1 
 
Low2 Unclear
3 
Unclear3 Unclear3 Low4 Low/unclear5 
Comments:  
1) No information was provided on random sequence generation. However, this does not mean 
that there would be problems in this respect.  
2) Telephone randomisation. 
3) The protocol or related articles does not clearly describe the nature of blinding. 
4) All the relevant outcomes were reported but some of the additional outcomes (unrelated to 
this assessment) were not found in the publication. 
5) Study was terminated early due to DMC recommendation after a signal for early mortality 
was seen in the daunorubicin 90 mg/m2 arm of the trial, without any corresponding signal 
suggesting a later reduction in relapse. Follow-up was complete by 1st January 2014, with a 
median follow-up for survival of 14.8 months (range, 2.5–27.6) and results are available for 
this period. Furthermore, results from longer follow-up, based on subgroup of FLT3 positive 
patients is published [11] .  
Abbreviations: see List of abbreviations. 
Sources: [17], [10], [11], [56] 
 
Table A13: Risk of bias – outcome level (RCTs) 
Outcome 
Trial 
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R
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f 
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l 
Overall survival 
RATIFY (CALGB 
10603/ 
CPKC412A2301) 
Low Low Low Low Low 
UK NCRI AML17 trial- 
subgroup analysis1  
Low High2 Low Low High3 
Overall survival censored at the time of SCT 
RATIFY (CALGB 
10603/ 
CPKC412A2301) 
Low Low Low Low Low 
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Outcome 
Trial 
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Event-free survival [EFS] 
RATIFY (CALGB 
10603/ 
CPKC412A2301) 
Low Low Low Low Low 
Disease-free survival [DFS] 
RATIFY (CALGB 
10603/ 
CPKC412A2301) 
Low Low Low Low Low 
Complete response [CR] 
RATIFY (CALGB 
10603/ 
CPKC412A2301) 
Low Low Low Low Low 
Cumulative incidence of relapse [CIR] 
RATIFY (CALGB 
10603/ 
CPKC412A2301) 
Low Low Low Low Low 
comments:  
1) This trial is evaluated only in terms of OS based on FLT3 positive patients of which is a sub-group 
of the whole trial population. The results of this trial is used only in OS section in this assessment. 
2) Analysis of FLT3 positive patients is based on a sub-group of the FAS ITT population. Furthermore, 
FLT3 status of approximately 8% of the original trial population was unknown and these patients 
were not included into subgroup-analysis.  
3) Main reasons for this judgement relies on the fact that the results are based on updated results of 
the sub-group analysis after 3-year follow-up, and those from full ITT population. The analysis 
seems to be post hoc and background information regarding of this analysis is very limited and 
described not enough in detail in [11]. 
Abbreviations: see List of abbreviations. 
Sources: [17], [10], [11], [56] 
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Table A14: Template for GRADE assessment  
Quality assessment Summary of findings Importance 
Number of patients Effect  Quality 
Number 
of 
studies  
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecisio
n 
Other 
consideration
s 
[Intervention] [comparison] Relative 
(95% CI) 
Absolute 
(95% CI) 
Overall survival – comparison of midostaurin in combination with standard induction and consolidation therapy vs. standard induction and consolidation therapy 
1 RCT Not 
serious 
Not applicable Not serious Not serious None 
 
360 357 HR=0.77 
(0.63–
0.95) 
Median 
OS was 
25.6 
months 
(18.6–
42.9) for 
placebo 
and 74.7 
months 
(31.5–not 
estimable
) for 
midostau
rin-based 
therapy. 
 
High Critical 
Overall survival – comparison of standard induction and consolidation therapy with high-dose daunorubicin (90 mg/m2) used in induction vs. midostaurin in combination 
with standard induction and consolidation therapy 
2 RCT Serious
1 
Not applicable Serious Serious Full details of 
the FLT3 
mutated 
subpopulation 
were not 
available were 
not available 
for the study 
comparing 90 
mg/m2 and 60 
mg/m2 
  HR=0.84 
(0.54–
1.31) 
— Low/Ve
ry low 
 
Critical/Impo
rtant 
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Quality assessment Summary of findings Importance 
Number of patients Effect  Quality 
Number 
of 
studies  
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecisio
n 
Other 
consideration
s 
[Intervention] [comparison] Relative 
(95% CI) 
Absolute 
(95% CI) 
daunorubicin, 
and thus does 
not allow 
assessment of 
similarity of the 
patient groups 
compared 
indirectly.  
Estimate for 
daunorubicin 
90 mg/m2 
effect is based 
on subgroup 
analysis. 
Follow-up time 
for OS differ 
between the 
UK NCRI 
AML17 and 
RATIFY trials, 
being only 3 
years in the 
former. 
Overall survival censored at the time of SCT – comparison of midostaurin in combination with standard induction and consolidation therapy vs. standard induction and 
consolidation therapy 
1 RCT Not 
serious 
Not applicable Not serious Not serious None 360 357 HR=0.75 
(0.54–
1.03) 
Medians 
were 
achieved 
neither in 
midostauri
n nor 
placebo 
High Important 
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Quality assessment Summary of findings Importance 
Number of patients Effect  Quality 
Number 
of 
studies  
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecisio
n 
Other 
consideration
s 
[Intervention] [comparison] Relative 
(95% CI) 
Absolute 
(95% CI) 
groups 
Event-free Survival [EFS] – comparison of midostaurin in combination with standard induction and consolidation therapy vs. standard induction and consolidation therapy 
1 RCT Not 
serious 
Not applicable Not serious Not serious None 360 357 HR 0.73 
(0.61–
0.87) 
Median 
EFS was 
10.2 for 
midostauri
n and 5.6 
months for 
placebo 
arms. 
High Important 
Disease-free Survival [DFS] from first complete response [CR] – comparison of midostaurin in combination with standard induction and consolidation therapy vs. 
standard induction and consolidation therapy 
1 RCT Not 
serious 
Not applicable Not serious Not serious None 360 357 HR 0.66 
(0.52–
0.85) 
Median 
DFS was 
28.1 for 
midostauri
n and 14.1 
months for 
placebo 
arms. 
High Important 
Complete response [CR; all CRs occurring during the induction] – comparison of midostaurin in combination with standard induction and consolidation therapy vs. 
standard induction and consolidation therapy 
1 RCT Not 
serious 
Not applicable Not serious Not serious None 360 357 RR=1.122 
(1.00–
1.26) 
Proportion 
of patients 
with CR 
was 65.0% 
for 
midostauri
n and 
58.0% 
months for 
High Important 
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Quality assessment Summary of findings Importance 
Number of patients Effect  Quality 
Number 
of 
studies  
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecisio
n 
Other 
consideration
s 
[Intervention] [comparison] Relative 
(95% CI) 
Absolute 
(95% CI) 
placebo 
arms. This 
converts to 
absolute 
risk-
reduction 
of 7% (-
0.12–
14.12)2. 
The point 
estimate 
equals to 
NNT 
(number 
needed to 
treat) = 
142. 
Cumulative Incidence of Relapse [CIR] – comparison of midostaurin in combination with standard induction and consolidation therapy vs. standard induction and 
consolidation therapy 
1 RCT Not 
serious 
Not applicable Not serious Not serious None 234 207 HR=0.68 
(0.52–
0.89) 
 
Median for 
CIR was 
not 
achieved 
for 
midostauri
n. Median 
CIR was 
17.6 
months for 
placebo 
group. 
High Important 
comments:  
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Quality assessment Summary of findings Importance 
Number of patients Effect  Quality 
Number 
of 
studies  
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecisio
n 
Other 
consideration
s 
[Intervention] [comparison] Relative 
(95% CI) 
Absolute 
(95% CI) 
1) See table A5 and comments related to sub-group analysis of UK AML 17 trial. 
2) Calculated by assessors. 
Abbreviations: see List of abbreviations. 
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Applicability tables 
 
Table A15: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The average age of patients in RATIFY trial was 45.2 years, which is likely to be less than 
the average age of those typically treated in clinical practice. It is also expected that 
midostaurin will be used also on patients over 60 years of age. However, patients over 60 
years old have not been studied in RCT setting and there is little evidence available 
concerning elderly population even though age itself is not the limiting factor when using 
midostaurin but rather patients’ fit for chemotherapy.  
Another feature of the patients in the RATIFY trial is the high proportion (57%) of patients 
receiving SCT. Also, MAH had expected lower proportion in the original sample size 
calculation. Possible explanation could be that the recruited patients are younger than 
those typically treated in clinical practice and furthermore (as typical for trials) are a 
selected sample of the population of interest. 
Intervention See below (comparators) 
Comparators It is likely that there is variation in the standard induction and consolidation chemotherapy 
across countries and regions. Midostaurin has been studied in combination with standard 
daunorubicin and cytarabine induction and high dose cytarabine consolidation 
chemotherapy, and with patients in complete response followed by midostaurin 
monotherapy. There is no evidence of midostaurin in combination with other induction and 
consolidation alternatives except those used in RATIFY. 
Outcomes There is evidence regarding OS for a long follow-up. Clinical benefits that support OS have 
also been demonstrated. Clear limitation related to applicability of the results in terms of 
outcomes, is the lack of HrQoL data. 
Setting No setting related applicability issues. 
Abbreviations: see List of abbreviations. 
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APPENDIX 2: REGULATORY AND REIMBURSEMENT STATUS 
Midostaurin received European market authorization via central procedure and will obtain market 
authorization in all European and EEA countries. Reimbursement status could not be decided in 
the member states at the time this assessment was written. 
Daunorubicin and cytarabine are extensively used all over Europe and are reimbursed in all Euro-
pean/EEA countries.  
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APPENDIX 3: CHECKLIST FOR POTENTIAL ETHICAL, ORGANISATIONAL, 
PATIENT AND SOCIAL AND LEGAL ASPECTS 
1. Ethical  
1.1. Does the introduction of the new medicine and its potential use/non-use in-
stead of the defined, existing comparator(s) give rise to any new ethical is-
sues? 
No 
1.2. Does comparing the new medicine to the defined, existing comparators point 
to any differences which may be ethically relevant? 
No 
Example: The marketing authorisation holder claims that its product is superior, but has decided to limit the 
amount of the new medicine, which means that it has to be rationed and not all patients who need it can 
receive it. The comparator is freely available. 
2. Organisational  
2.1. Does the introduction of the new medicine and its potential use/non-use in-
stead of the defined, existing comparators require organisational changes? 
No 
2.2. Does comparing the new medicine to the defined, existing comparators point 
to any differences which may be organisationally relevant? 
No 
Examples: The new medicine will replace a surgical intervention which may lead to excess capacity in rele-
vant areas. The new intervention requires the establishment of specialised centres for administration 
3. Social  
3.1. Does the introduction of the new medicine and its potential use/non-use in-
stead of the defined, existing comparator(s) give rise to any new social is-
sues? 
No 
3.2. Does comparing the new medicine to the defined, existing comparators point 
to any differences which may be socially relevant? 
No 
Example: A medicine which is widely used by persons with abuse problems and which colours the tongue 
blue, thus immediately identifying the user as such. Comparators do not have this property. 
4. Legal  
4.1. Does the introduction of the new medicine and its potential use/non-use in-
stead of the defined, existing comparator(s) give rise to any legal issues? 
No 
4.2. Does comparing the new medicine to the defined, existing comparators point 
to any differences which may be legally relevant? 
No 
Examples: The comparator for the new medicine is a pharmaceutical which is not licensed in the indication 
of concern, but widely in use. 
The comparator for the new pharmaceutical is a controlled, restricted substance, the new medicine 
is not. 
Note: The assessment should not address patent-related issues. 
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For the purpose of transparency, a separate document with comments on the 3rd draft 
assessment from external experts and the MAH/manufacturer(s) (factual accuracy check), 
as well as responses from authors, is available on the EUnetHTA website. Please find the 
link here.  
